08-14-00 Seq. A

TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING

Certification under 37 CFR 1.10 (if applicable)

EL154221135US
"Express Mail" mailing label number

August 11, 2000
Date of Deposit

I hereby certify that this Transmittal letter, enclosed application, and any other documents referred to as enclosed herein, are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Cederic Rodgers
(Typed or printed name of person mailing application)

Cederic Rodgers
(Signature of person mailing application)

ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
Washington, D.C. 20231

Attorney Docket No. TSRI 710.2

Customer Number 002387

Sir:

Transmitted herewith for filing is the utility patent application of inventor(s): John Hood, Brian Eliceiri and David A. Cheresh.

and entitled: **METHODS AND COMPOSITIONS USEFUL FOR MODULATION OF ANGIOGENESIS USING TYROSINE KINASE RAF AND RAS**

1. **Type Of Application**

This application is:

___ an original (nonprovisional) application.
___ a divisional of prior application Serial No. _____.
___ a continuation of prior application Serial No. _____.
___ a continuation-in-part of prior application Serial No.
X an application claiming priority of U.S. Provisional Application Nos. 60/148,924 and 60/215,951

___ The entire disclosure of the prior application is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

___ The prior application is assigned of record to: _____

___ Additional prior application information: Examiner _____ Group _____

2. Enclosed **Application Elements** are:

X A duplicate copy of this transmittal letter,
X specification (including claims and abstract) containing 60 pages,
X drawings: ___ 1 copy of _____ sheet(s) of formal drawings, **OR**
X 1 copy of Twenty (20) sheet(s) of informal drawings. (Figs. 1-20B)
___ an executed declaration or oath for the utility patent application including a power of attorney, **OR**
X an unexecuted declaration or oath for the utility patent application including a power of attorney, **OR**
___ a copy of an executed declaration or oath including power of attorney from a priority application,
___ statement deleting inventor(s) named in the priority application
___ Microfiche Computer Program
X nucleotide and/or amino acid sequence
a. X computer readable copy
b. X paper copy
c. X statement verifying above copies

3. Enclosed **Accompanying Application Parts** are:

__ One (1) Verified Statement(s) relating to small entity status.
__ Copy of verified statement filed in prior application; status still proper and desired.
__ Preliminary Amendment
__ Claim cancellations are indicated in Preliminary Amendment
X one itemized, stamped, and self-addressed postcard for the PTO Mail Room date stamp.
__ English translation document
__ Information Disclosure Statement including Form PTO-1449 and copies of the citations therein.

4. Filing Fees (as calculated below)

	(Col. 1)	(Col. 2)		
For:	Number Filed	Number Extra	Rate	Fee
Basic Fee				$ 690
Total Claims	67 — 20	47	x $ 18 =	$ 846
Independent Claims	13 - 3	10	x $ 78 =	$ 780
Multiple Dependent Claim Presented (if applicable)			+ $260 =	$ N/A
			Subtotal	$ 2,316
			Reduction by 50% for filing by small entity	$ -0-
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.			TOTAL	$ 2,316

__ Please charge my Deposit Account No. 15-0508 in the amount of $_____.
X A check in the amount of $2,316.00 to cover the filing fee is enclosed.
X The Commissioner is authorized to charge payment of the following amounts associated with this communication or credit any overpayment to Deposit Account No. 15-0508:
  X Additional filing fees under 37 CFR 1.16 or deficiencies in remittances therefor.
  X Additional processing fees under 37 CFR 1.17 or deficiencies in remittances therefor.
X **ONLY if applicant has partially paid** the patent issue fee under 37 C.F.R. §1.18, then the **deficiency** shall be charged to Deposit Account No. 15-0508, and the Commissioner is authorized to so charge the Deposit Account.
X The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 15-0508 for any fee that may be due in connection with such a request for an extension of time.

Date: August 11, 2000

Attorney's Signature _____
Mark Chao (Reg. No. 37,293)

Correspondence Address:
Mark Chao (Reg. No. 37,293)
OLSON & HIERL, LTD.
20 North Wacker Drive, 36th Floor
Chicago, Illinois 60606
Telephone: (312) 580-1180

METHODS AND COMPOSITIONS USEFUL FOR MODULATION OF ANGIOGENESIS USING PROTEIN KINASE RAF AND RAS

Cross-reference to Related Applications

This application claims priority to U.S. Provisional Patent Application Serial No. 60/215,951 filed July 5, 2000, and United States Provisional Patent Application Serial No. 60/148,924, filed August 13, 1999.

Technical Field

The present invention relates generally to the field of medicine, and relates specifically to methods and compositions for modulating angiogenesis of tissues using the protein kinase Raf or Ras, variants of Raf or Ras, using reagents which modulate Raf or Ras, and using nucleic acids encoding them.

Background

Angiogenesis is a process of tissue vascularization that involves the growth of new blood vessels into a tissue, and is also referred to as neo-vascularization. The process is mediated by the infiltration of endothelial cells and smooth muscle cells. The process is believed to proceed in any one of three ways: the vessels can sprout from pre-existing vessels, de-novo development of vessels can arise from precursor cells (vasculogenesis), or existing small vessels can enlarge in diameter. Blood et al., Bioch. Biophys. Acta, 1032:89-118 (1990).

Angiogenesis is an important process in neonatal growth, but is also important in wound healing and in the pathogenesis of a large variety of clinical diseases including tissue inflammation, arthritis, tumor growth, diabetic retinopathy, macular degeneration by neovascularization of the retina and like conditions. These clinical manifestations associated with angiogenesis are referred to as angiogenic diseases. Folkman et al., Science, 235:442-447 (1987). Angiogenesis is generally absent in adult or mature tissues, although it does occur in wound healing and in the corpus luteum growth cycle. See, for example, Moses et al., Science, 248:1408-1410 (1990).

It has been proposed that inhibition of angiogenesis would be a useful therapy for restricting tumor growth. Inhibition of angiogenesis has been proposed by (1)

inhibition of release of "angiogenic molecules" such as bFGF (basic fibroblast growth factor), (2) neutralization of angiogenic molecules, such as by use of anti-bFGF antibodies, (3) use of inhibitors of vitronectin receptor $\alpha_v\beta_3$, and (4) inhibition of endothelial cell response to angiogenic stimuli. This latter strategy has received attention, and Folkman et al., Cancer Biology, 3:89-96 (1992), have described several endothelial cell response inhibitors, including collagenase inhibitor, basement membrane turnover inhibitors, angiostatic steroids, fungal-derived angiogenesis inhibitors, platelet factor 4, thrombospondin, arthritis drugs such as D-penicillamine and gold thiomalate, vitamin D_3 analogs, alpha-interferon, and the like that might be used to inhibit angiogenesis. For additional proposed inhibitors of angiogenesis, see Blood et al., Bioch. Biophys. Acta., 1032:89-118 (1990), Moses et al., Science, 248:1408-1410 (1990), Ingber et al., Lab. Invest., 59:44-51 (1988), and United States Patent Nos. 5,092,885, 5,112,946, 5,192,744, 5,202,352, 5,753,230 and 5,766,591. None of the inhibitors of angiogenesis described in the foregoing references involve the Raf proteins, however.

For angiogenesis to occur, endothelial cells must first degrade and cross the blood vessel basement membrane in a manner similar to that used by tumor cells during invasion and metastasis formation.

It has been previously reported that angiogenesis depends on the interaction between vascular integrins and extracellular matrix proteins. Brooks et al., Science, 264:569-571 (1994). Furthermore, it was reported that programmed cell death (apoptosis) of angiogenic vascular cells is initiated by the interaction, which would be inhibited by certain antagonists of the vascular integrin $\alpha_v\beta_3$. Brooks et al., Cell, 79:1157-1164 (1994). More recently, it has been reported that the binding of matrix metalloproteinase-2 (MMP-2) to vitronectin receptor ($\alpha_v\beta_5$) can be inhibited using $\alpha_v\beta_5$ antagonists, and thereby inhibit the enzymatic function of the proteinase. Brooks et al., Cell, 85:683-693 (1996).

Summary of the Invention

The present invention contemplates modulation of angiogenesis in tissues where that angiogenesis depends upon the activity of protein kinase Raf, also referred to generically herein as Raf.

Compositions and methods for modulating angiogenesis in a tissue associated with a disease condition are contemplated. A composition comprising an angiogenesis-modulating amount of a Raf protein is administered to tissue to be treated for a disease condition that responds to modulation of angiogenesis. The composition providing the Raf protein can contain purified protein, biologically active protein fragments, recombinantly produced Raf protein or protein fragments or fusion proteins, or gene/nucleic acid expression vectors for expressing a Raf protein.

Where the Raf protein is inactivated or inhibited, the modulation is an inhibition of angiogenesis. Where the Raf protein is active or activated, the modulation is a potentiation of angiogenesis.

The tissue to be treated can be any tissue in which modulation of angiogenesis is desirable. For angiogenesis inhibition, it is useful to treat diseased tissue where deleterious neovascularization is occurring. Exemplary tissues include inflamed tissue, solid tumors, metastases, tissues undergoing restenosis, and the like tissues.

For potentiation, it is useful to treat patients with hypoxic tissues such as those following stroke, myocardial infarction or associated with chronic ulcers, tissues in patients with ischemic limbs in which there is abnormal, i.e., poor circulation, due to diabetic or other conditions. Patients with chronic wounds that do not heal, and therefore could benefit from the increase in vascular cell proliferation and neovascularization, can be treated as well.

Particularly preferred is the use of Raf protein containing a modified amino acid sequence as described herein. Several particularly useful modified Raf proteins, including Raf fusion proteins such as Raf-caax and nucleic acid constructs which encode for the expression thereof are described herein and are within the purview of the present invention.

The present invention also encompasses a pharmaceutical composition suitable for inhibiting angiogenesis in a target mammalian tissue comprising a viral or non-viral gene transfer vector containing a nucleic acid, the nucleic acid having a nucleic acid segment encoding for a Raf protein, and the Raf protein having any amino acid residue at codon 375 except for lysine, and a pharmaceutically acceptable carrier or excipient. A particularly preferred embodiment utilizes Raf protein designated as Raf K375M and described in the examples below. Another inactive Raf construct is a nucleic acid which encodes for a Raf protein having the carboxy terminal portion deleted. One preferred embodiment utilizes a Raf protein designated Raf 1-305, which is an inactive Raf protein.

Also envisioned is a pharmaceutical composition suitable for stimulating angiogenesis in a target mammalian tissue and comprising a viral or non-viral gene transfer vector containing a nucleic acid having a segment encoding for a Raf protein having kinase activity and a pharmaceutically acceptable carrier or excipient therefor. A preferred nucleic acid encodes for an inhibitory Raf fusion protein that is Raf-caax. Another inhibitory Raf construct contains a nucleic acid encoding for a Raf protien having the amino terminal portion of the protein deleted. One preferred embodiment utilizes a Raf protein designated Raf 306-648, and described in the examples below.

The invention further contemplates modulation of angiogenesis in tissues by small GTPase Ras, also referred to generically herein as Ras, due to its role in signaling Raf, as described herein. Also envisioned is the modulation of angiogenesis in tissues utilizing the combination of Ras and Raf modulation. Such combined modulation can take the form of a single administration of combined formulations of protein, or nucleic acid encoding modulating protein, or the separate administration of individual doses, in an angiogenesis-modulating amout.

Compositions and methods for modulating angiogenesis in a tissue, associated with a disease condition are contemplated, where the modulation is directed to the Raf-mediated angiogenesis pathway via the Ras protein. A composition comprising an angiogenesis-modulating amount of a Ras protein is administered to tissue to be

treated for a disease condition that responds to modulation of angiogenesis. The composition providing the Ras protein can contain purified protein, biologically active Ras protein fragments, recombinantly produced Ras protein or protein fragments or fusion proteins, or gene/nucleic acid expression vectors for expressing a Ras protein.

Where the Ras protein is inactivated or inhibited, the modulation is an inhibition of angiogenesis. Where the Ras protein is active or activated, the modulation is a potentiation of angiogenesis. Pharmaceutical compositions and methods of use for dominant negative Ras proteins, such as S17N Ras or V12C40 Ras, are contemplated for use in a manner similar to that for proteins of the Raf family. In a further aspect of this invention, pharmaceutical compositions and methods of use for dominant active Ras proteins, such as G12V Ras or V12S35 Ras, are contemplated for uses comparable to those for the Raf family proteins.

Further contemplated are methods for modulating angiogenesis in a tissue associated with a disease condition comprising administering an angiogenesis modulating amount of a pharmaceutical composition comprising a Raf protein or a nucleotide sequence capable of expressing Raf protein, and a Ras protein or a nucleotide sequence capable of expressing Ras protein. In such methods, where the desired modulation is an inhibition of angiogenesis, at least one or both of the Raf or Ras proteins is inactive. Where the desired modulation is a stimulation of angiogenesis, at least one or both of the Raf or Ras proteins are active.

Brief Description of the Drawings

In the drawings forming a portion of this disclosure:

FIGs. 1A-1D illustrate that ecotrophically packaged retrovirus only infects murine cells. Ecotrophic packaging cells were transfected with a retroviral construct encoding the b-Galactosidase (b-Gal) gene and the supernatant collected 24 hours later. Supernate containing the virus was placed on either murine-derived fibroblasts (FIG. 1A), murine-derived endothelial cells (FIG. 1B), human epithelial adenocarcinoma cells (FIG. 1C), or human melanoma cells (FIG. 1D) for 24 hours. b-Gal activity was visualized using standard methods.

FIG. 2 illustrates that bFGF-induced increases in Raf activity were blocked by prior infection with Raf K375M in a mouse endothelial cell line. Ecotrophic packaging cells were transfected with a retroviral construct encoding the defective Raf kinase gene and the supernatant collected 24 hours later. Supernate containing virus was placed on mouse endothelial cells for 24 hours. Cells were then treated with bFGF for 5 minutes and lysed. Raf kinase activity was quantified by the ability of immunoprecipitated Raf kinase to phosphorylate the MEK substrate with radioactively labeled ^{32}P. Reaction mixtures were fractionated by SDS PAGE and quantified using scanning densitometry.

FIGs. 3A-3B illustrate that mutant inactive Raf K375M blocks bFGF-induced angiogenesis in a murine subcutaneous angiogenesis model. Angiogenesis was induced by injecting 250 ul of ice-cold, growth factor-reduced matrigel containing 400 ng/ml bFGF, with or without retrovirus expressing packaging cells that express Raf K375M, subcutaneously in the mouse flank. Five days later endothelial-specific FITC-conjugated Bandeiriea Simplifica B5 lectin was injected via the tail vein and allowed to circulate and clear for 30 minutes. Angiogenesis was then quantitated by removing, extracting, and assaying the angiogenic tissue for fluorescent content (FIG. 3A). Neovascularization was confirmed by optical sectioning (FIG. 3B).

FIGs. 4A-4B illustrate that mutationally active Raf stimulates angiogenesis in a murine subcutaneous angiogenesis model. Angiogenesis was induced by injecting 250 ul of ice-cold, growth factor-reduced matrigel containing retrovirus expressing packaging cells which express GFP control or amino terminal deleted Raf kinase (Raf 306-648), subcutaneously in the mouse flank. Five days later angiogenesis was then quantitated by removing, extracting, and assaying the angiogenic tissue for fluorescent content (FIG. 4A). Neovascularization was confirmed by sectioning and staining with Mason's trichrome (FIG. 4B).

FIGs. 5A-5D illustrate retroviral delivery of Raf K375M kinase to the tumor induced apoptosis in an endothelial-specific manner. Human tumors were injected subcutaneously on the flank of athymic wehi (nu/nu) mice and allowed to implant.

When tumors reached 100 mm^3 they were injected intratumorally with culture supernate containing 10^6 pfu of ecotrophically packaged Raf K375M. Forty-eight hours later the tumor was harvested, sectioned, and immunohistochemistry performed. Endothelial cells were identified by vWF expression (FIG. 5A), while the Flag tag marker was used to indicate cells infected by the Raf K375M kinase gene (FIG. 5B). Each of these markers are seen colocalized with the TUNEL marker indicative of apoptotic cells (FIGs. 5C & 5D).

FIGs. 6A-6B illustrate endothelial delivery of the Raf K375M kinase gene inhibited tumor growth and stimulated tumor regression. Human tumors were injected subcutaneously on the flank of athymic wehi (nu/nu) mice and allowed to grow to 100 mm^3. At this point either a single injection of packaging cells expressing Raf K375M kinase was performed at a tumor-adjacent site or a series of intratumoral injections of viral supernate was initiated. This strategy resulted in rapid regressions of the tumors which was not seen with injection of the control GFP gene (FIG. 6A). This regression occurred rapidly and was maintained throughout the length of the experiment (FIG. 6B).

FIG. 7 depicts a cDNA sequence encoding for human c-Raf which is the complete coding sequence with the introns deleted. The sequence is accessible through GenBank Accession Number X03484 (GI=35841, HSRAFR). (SEQ ID NO.: 1).

FIG. 8 depicts the encoded translated amino acid residue sequence of human c-Raf of the coding sequence depicted in the nucleic acid sequence shown in FIG. 7. (SEQ ID NO.: 2).

FIG. 9 illustrates that angiogenesis is dependent on activation of the Ras-Raf-MEK-ERK pathway. Ras activity was elevated in chick chorioallantoic membrane (CAM) lysates exposed to bFGF as determined by a Ras pulldown assay. CAMs from 10-day old chick embryos were stimulated topically with filter disks saturated with either PBS or 30 nanograms (ng) of bFGF. After 5 minutes, CAM tissue was resected, homogenized in lysis buffer, and Ras activity was then determined

by its capacity to be precipitated by a GST fusion peptide encoding the Ras binding domain of Raf. Because only active Ras binds Raf, a recombinant protein was generated consisting of the Ras binding domain of Raf conjugated to glutathione-S-transferase (GST). In turn GST was conjugated to sepharose beads enabling the precipitation of active Ras from a tissue lysate.

FIG. 10 depicts the cDNA coding domain nucleotide sequence of wild-type human Ras (wt H-Ras). (SEQ ID NO.: 3). A complete coding sequence for c-Ha-Ras1 proto-oncogene is accessible through GenBank (GI=190890, HUMRASH). (SEQ ID NO.: 5).

FIG. 11 depicts the amino acid residue sequence encoded by the cDNA nucleotide sequence of wild-type human Ras (wt H-Ras) shown in FIG. 10. (SEQ ID NO.: 4).

FIG. 12 illustrates that infection with mutant null Ras blocked growth factor-induced angiogenesis in the CAM. Fifteen microliters (ul) of high titer Chicken sarcoma retrovirus, RCAS(A), encoding mutant null Ras, S17N Ras (wild type H-Ras with a substitution of Asn for Ser at position 17), was topically applied to filter disks on CAMs as stimulated with bFGF as described in FIG. 9. Angiogenesis was assessed after 72 hours by counting vessel branch points.

FIGs. 13A and 13B illustrate schematically and graphically respectively that infection with a mutant Ras construct, Ras V12S35, which selectively activates the Ras-Raf-MEK-ERK pathway, induced angiogenesis, whereas a mutant construct, Ras V12C40, which selectively activates the PI3K pathways, did not. Fifteen ul of high titer RCAS (A) virus encoding the Raf-MEK-ERK activating Ras construct, Ras V12S35, or the PI3 kinase activating Ras construct, Ras V12C40, were topically applied to filter disks and results assessed as described in FIG. 12.

FIG. 14 depicts the nucleotide sequence encoding the fusion protein Raf-caax, where the nucleotide sequence encoding the carboxy terminus of human Raf (wt H-Raf) is fused with a nucleotide sequence of encoding a 20 amino acid residue sequence of the K-Ras membrane localization domain. (SEQ ID NO.: 6).

FIG. 15 depicts the amino acid residue sequence of Raf-caax, the fusion protein generated from the fusion nucleotide sequence depicted in FIG. 14. (SEQ ID NO.: 7).

FIGs. 16A-16E and FIG. 16F, respectively, pictorially and graphically illustrate that the MEK inhibitor, PD98059, blocked angiogenesis induced by either mutant active Ras or Raf. Virus encoding the activating Ras construct, Ras V12 (also referred to as G12V, and the activating Raf construct, Raf-caax, were topically applied to filter disks as described in FIG. 12. After 24 hours, one (1) nanomole of the MEK inhibitor, PD98059, was added to the disk. The CAMs were then evaluated as described in FIG. 12. Data plotted is the mean ± SE of 20 embryos.

FIGs. 17A-17F and FIG. 17G, respectively, pictorially and graphically illustrate that angiogenesis induced by Raf, but not Ras, was refractory to inhibition by integrin blockade. Infection with both mutant active Ras and Raf constructs induced pronounced angiogenesis, but only Ras-induced angiogenesis was inhibited by $\alpha_v\beta_3$ integrin-blocking antibodies. CAMs from 10-day old chick embryos were stimulated as described in FIGs. 9 and 12 with filter disks saturated with either PBS (control), bFGF, the RCAS(A) retroviral constructs G12V-Ras or Raf-caax. LM609, a monoclonal antibody to integrin $\alpha_v\beta_3$, was intravenously delivered after 24 hours and angiogenesis was assessed by vessel branch point analysis after 72 hours. Representative CAMs are shown in the inset. Data is the mean ± SE of 20 embryos.

FIGs. 18A-18D and 18E, respectively, pictorially and graphically illustrate that co-infection of CAMs with a mutant null focal adhesion kinase, FRNK, blocked Ras, but not Raf-induced angiogenesis. RCAS(A) viruses encoding Ras V12 or Raf-caax were topically applied as described in FIG. 12 along with RCAS(B) virus encoding FAK-related-null-kinase (FRNK) to the CAM filter disk. Data is the mean ± SE of 20 embryos.

FIGs. 19A and 19B-19G, respectively, graphically and pictorially, illustrate that FRNK blocked bFGF and Ras-, but not Raf, -induced angiogenesis in a murine subcutaneous angiogenesis model. Angiogenesis was induced by injecting 250 ul of

ice-cold, growth factor-reduced matrigel containing either 400 ng/ml bFGF or Moloney retrovirus expressing packaging cells expressing the described gene, subcutaneously in the mouse flank. FRNK retrovirus was added to matrigel as high titer virus packaged with the vsv.g coat protein. Five days later, endothelial-specific FITC-conjugated Bandeiriea Simplifica B5 lectin was injected via the tail vein and allowed to circulate. Angiogenesis was then quantitated by removing, extracting, and assaying the angiogenic tissue for fluorescent content.

FIGs. 20A and 20B illustrate that co-infection of CAMs with a mutant null focal adhesion kinase, FRNK, blocked Ras-induced activation of Raf. CAMs were treated as described in FIG. 18 with the exception that after 24 hours the angiogenic tissue was resected, solubilized, Raf immunoprecipitated, and Raf activity assessed by its capacity to phosphorylate kinase-dead MEK. FIG. 20A shows the immunoprecipated active versus total Raf proteins assayed under each of the combinations above the results. FIG. 20B graphically plots the results of the active Raf determinations under those conditions.

Detailed Description of the Invention

A. Definitions

Amino Acid Residue: An amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH_2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature (described in J. Biol. Chem., 243:3552-59 (1969) and adopted at 37 CFR §1.822(b)(2)).

It should be noted that all amino acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the

beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues.

Polypeptide: refers to a linear series of amino acid residues connected to one another by peptide bonds between the alpha-amino group and carboxy group of contiguous amino acid residues.

Peptide: as used herein refers to a linear series of no more than about 50 amino acid residues connected one to the other as in a polypeptide.

Cyclic peptide: refers to a compound having a heteroatom ring structure that includes several amide bonds as in a typical peptide. The cyclic peptide can be a "head to tail" cyclized linear polypeptide in which a linear peptide's n-terminus has formed an amide bond with the -terminal carboxylate of the linear peptide, or it can contain a ring structure in which the polymer is homodetic or heterodetic and comprises amide bonds and/or other bonds to close the ring, such as disulfide bridges, thioesters, thioamides, guanidino, and the like linkages.

Protein: refers to a linear series of greater than 50 amino acid residues connected one to the other as in a polypeptide.

Fusion protein: refers to a polypeptide containing at least two different polypeptide domains operatively linked by a typical peptide bond ("fused"), where the two domains correspond to peptides not found fused in nature.

Synthetic peptide: refers to a chemically produced chain of amino acid residues linked together by peptide bonds that is free of naturally occurring proteins and fragments thereof.

B. General Considerations

The present invention relates generally to the discovery that angiogenesis is mediated by the protein kinase Raf protein, and that angiogenesis can be modulated by providing either active or inactive Raf proteins for potentiating or inhibiting angiogenesis, respectively. The invention also relates to the discovery that a Ras protein can affect Raf, and thereby modulate angiogenesis.

This discovery is important because of the role that angiogenesis, the formation of new blood vessels, plays in a variety of disease processes. On the other hand, where tissues associated with a disease condition require angiogenesis for tissue growth, it is desirable to inhibit angiogenesis and thereby inhibit the diseased tissue growth. Where injured tissue requires angiogenesis for tissue growth and healing, it is desirable to potentiate or promote angiogenesis and thereby promote tissue healing and growth.

Where the growth of new blood vessels is the cause of, or contributes to, the pathology associated with a disease tissue, inhibition of angiogenesis will reduce the deleterious effects of the disease. By inhibiting angiogenesis, one can intervene in the disease, ameliorate the symptoms, and in some cases cure the disease.

Examples of tissue associated with disease and neovascularization that will benefit from inhibitory modulation of angiogenesis include cancer, rheumatoid arthritis, ocular diseases such as diabetic retinopathy, inflammatory diseases, restenosis, and the like. Where the growth of new blood vessels is required to support growth of a deleterious tissue, inhibition of angiogenesis reduces the blood supply to the tissue and thereby contributes to reduction in tissue mass based on blood supply requirements. Particularly preferred examples include growth of tumors where neovascularization is a continual requirement in order that the tumor grow beyond a few millimeters in thickness, and for the establishment of solid tumor metastases.

Where the growth of new blood vessels contributes to healing of tissue, potentiation of angiogenesis assists in healing. Examples include treatment of patients with ischemic limbs in which there is abnormal, i.e. poor circulation as a result of diabetes or other conditions. Also contemplated are patients with chronic wounds which do not heal and therefore could benefit from the increase in vascular cell proliferation and neovascularization.

The methods of the present invention are effective in part because the therapy is highly selective for angiogenesis and not other biological processes.

As described earlier, angiogenesis includes a variety of processes involving neovascularization of a tissue including "sprouting", vasculogenesis, or vessel enlargement, all of which angiogenesis processes are affected by Raf protein alone or together with a Ras protein. With the exception of traumatic wound healing, corpus luteum formation and embryogenesis, it is believed that the majority of angiogenesis processes are associated with disease processes and therefore the use of the present therapeutic methods are selective for the disease and do not have deleterious side effects.

C. Raf Proteins

A protein kinase Raf protein for use in the present invention can vary depending upon the intended use. The terms "Raf protein" or "Raf" are used to refer collectively to the various forms of protein kinase Raf protein, either in active or inactive forms.

An "active Raf protein" refers to any of a variety of forms of Raf protein which potentiate, stimulate, activate, induce or increase angiogenesis. Assays to measure potentiation of angiogenesis are described herein, and are not to be construed as limiting. A protein is considered active if the level of angiogenesis is at least 10% greater, preferably 25% greater, and more preferably 50% greater than a control level where no Raf is added to the assay system. The preferred assay for measuring potentiation is the *in vitro* Raf kinase as described in the Examples in which MEK substrate is phosphorylated with ^{32}P. Exemplary active Raf proteins are described in the Examples.

An "inactive Raf protein" refers to any of a variety of forms of Raf protein which inhibit, reduce, impede, or restrict angiogenesis. Assays to measure inhibition of angiogenesis are described herein, and are not to be construed as limiting. A protein is considered inactive if the level of angiogenesis is at least 10% lower, preferably 25% lower, and more preferably 50% lower than a control level where no exogenous Raf is added to the assay system. The preferred assay for measuring

inhibition is the *in vitro* Raf kinase as described in the Examples in which MEK substrate is phosphorylated with ^{32}P. Exemplary inactive Raf proteins are described in the Examples.

A Raf protein useful in the present invention can be produced in any of a variety of methods including isolation from natural sources including tissue, production by recombinant DNA expression and purification, and the like. Raf protein can also be provided "in situ" by introduction of a gene therapy system to the tissue of interest which then expresses the protein in the tissue.

A gene encoding a Raf protein can be prepared by a variety of methods known in the art, and the invention is not to be construed as limiting in this regard. For example, the natural history of Raf is well known to include a variety of homologs from mammalian, avian, viral and the like species, and the gene can readily be cloned using cDNA cloning methods from any tissue expressing the protein. A preferred Raf for use in the invention is a cellular protein, such as the mammalian or avian homologs designated c-Raf. Particularly preferred is human c-Raf. A further preferred Raf protein of this invention is a fusion protein of Raf that is constitutively active but independent of Ras-mediated activation. Such a Raf protein can be a fusion protein. A preferred Ras-independent Raf protein is Raf-caax which is a carboxy terminal fusion protein of wild type Raf with the K-Ras membrane localization domain as further described in the Examples.

D. Ras Proteins

Ras family GTPases for use in the present invention can vary depending upon the intended use. The terms "Ras protein" or "Ras" are used herein to refer collectively to the various forms of Ras protein, either in active or inactive forms.

An "active Ras protein" refers to any of a variety of forms of Ras protein which potentiate, stimulate, activate, induce or increase angiogenesis. Assays to measure potentiation of angiogenesis by Ras are described herein, and are not to be construed as limiting. A protein is considered active if the level of angiogenesis is at

least 10% greater, preferably 25% greater, and more preferably 50% greater than a control level where no Ras is added to the assay system. Exemplary active Ras proteins are Ras G12V, also referred to as V12, and Ras V12S35, both of which are further described in the Examples.

An "inactive Ras protein" refers to any of a variety of forms of Ras protein which inhibit, impede, delay, or stop angiogenesis. Assays to measure inhibition of angiogenesis are described herein, and are not to be construed as limiting. A protein is considered inactive if the level of angiogenesis is at least 10% lower, preferably 25% lower, and more preferably 50% lower than a control level where no exogenous Ras is added to the assay system. Exemplary inactive Ras proteins include the null mutant Ras referred to as Ras S17N (or sometimes N17) and V12C40, both of which are further described in the Examples.

A Ras protein useful in the present invention can be produced in any of a variety of methods including isolation from natural sources including tissue, production by recombinant DNA expression and purification, and the like. Ras protein can also be provided "in situ" by introduction of a gene therapy system to the tissue of interest which then expresses the protein in the tissue.

A gene encoding a Ras protein can be prepared by a variety of methods known in the art. The present invention is not to be construed as limiting in this regard. For example, the natural history of Ras is well known to include a variety of homologs from mammalian, avian, viral and the like species, and the gene can readily be cloned using cDNA cloning methods from any tissue expressing the protein.

It is to be understood by the present teachings that a Ras protein in its collective forms can be used in the same various embodiments as is described herein for a Raf protein, and therefore, the details for using a Ras protein are not reiterated. For example, Ras may be presented in an active or inactive form for modulating angiogenesis, or may be provided by nucleic acid expression of the Ras protein product, through the use of vector delivery systems, and in various pharmaceutical (therapeutic) compositions and articles of manufacture for practicing the invention.

Methods of modulating angiogenesis using a Ras-based reagent in place of the recited Raf-based reagents are also contemplated.

E. Recombinant DNA Molecules and Expression Systems for Expression of a Raf or Ras Protein

The invention describes several nucleotide sequences of particular use in the present invention. These define nucleic acid sequences which encode for Raf or Ras protein useful in the invention, and various DNA segments, recombinant DNA (rDNA) molecules and vectors constructed for expression of Raf and/or Ras protein.

DNA molecules (segments) of this invention therefore can comprise sequences which encode whole structural genes, fragments of structural genes, and transcription units as described further herein.

A preferred DNA segment is a nucleotide sequence which encodes a Raf protein as defined herein, or biologically active fragment thereof.

Another preferred DNA segment is a nucleotide sequence which encodes a Ras protein as defined herein, or biologically active fragment thereof. By biologically active, it is meant that the expressed protein will have at least some of the biological activity of the intact protein found in a cell, such as ligand binding, or in the case of active forms of the protein, enzymatic activity.

The amino acid residue sequence and nucleotide sequence of a preferred c-Raf and h-Ras are described in the Examples.

A preferred DNA segment codes for an amino acid residue sequence substantially the same as, and preferably consisting essentially of, an amino acid residue sequence or portions thereof corresponding to a Raf or Ras protein described herein. Representative and preferred DNA segments are further described in the Examples.

The amino acid residue sequence of a protein or polypeptide is directly related via the genetic code to the deoxyribonucleic acid (DNA) sequence of the structural gene that codes for the protein. Thus, a structural gene or DNA segment can be

defined in terms of the amino acid residue sequence, i.e., protein or polypeptide, for which it codes.

An important and well known feature of the genetic code is its redundancy. That is, for most of the amino acids used to make proteins, more than one coding nucleotide triplet (codon) can code for or designate a particular amino acid residue. Therefore, a number of different nucleotide sequences may code for a particular amino acid residue sequence. Such nucleotide sequences are functionally equivalent since they can result in the production of the same amino acid residue sequence in all organisms. Occasionally, a methylated variant of a purine or pyrimidine may be incorporated into a given nucleotide sequence. However, such methylations do not affect the coding relationship in any way.

A nucleic acid is any polynucleotide or nucleic acid fragment, whether it be a polyribonucleotide of polydeoxyribonucleotide, i.e., RNA or DNA, or analogs thereof. In preferred embodiments, a nucleic acid molecule is in the form of a segment of duplex DNA, i.e, a DNA segment, although for certain molecular biological methodologies, single-stranded DNA or RNA is preferred.

DNA segments are produced by a number of means including chemical synthesis methods and recombinant approaches, preferably by cloning or by polymerase chain reaction (PCR). DNA segments that encode all or only portions of a Raf or Ras protein can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al, J. Am. Chem. Soc., 103:3185-3191 (1981), or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define the DNA segment, followed by hybridization and ligation of oligonucleotides to build the complete segment. Alternative methods include isolation of a preferred DNA segment by PCR with a pair of oligonucleotide primers used on a cDNA library believed to contain members which encode a Raf or Ras protein.

Of course, through chemical synthesis, any desired modifications can be made simply by substituting the appropriate bases for those encoding the native amino acid

residue sequence. This method is well known, and can be readily applied to the production of the various different "modified" Raf or Ras proteins described herein.

Furthermore, DNA segments consisting essentially of structural genes encoding a Raf or Ras protein can be subsequently modified, as by site-directed or random mutagenesis, to introduce any desired substitutions. It is understood that various allelic forms of Raf or Ras protein and genes encoding for Raf or Ras protein are also suitable for use in the present invention.

1. Cloning a Raf or Ras Gene

A Raf or Ras gene of this invention can be cloned from a suitable source of genomic DNA or messenger RNA (mRNA) by a variety of biochemical methods. Cloning these genes can be conducted according to the general methods described in the Examples and as known in the art.

Sources of nucleic acids for cloning a Raf or Ras gene suitable for use in the methods of this invention can include genomic DNA or messenger RNA (mRNA) in the form of a cDNA library, from a tissue believed to express these proteins. A preferred tissue is human lung tissue, although any other suitable tissue may be used.

A preferred cloning method involves the preparation of a cDNA library using standard methods, and isolating the Raf-encoding or Ras-encoding nucleotide sequence by PCR amplification using paired oligonucleotide primers based on the nucleotide sequences described herein. Alternatively, the desired cDNA clones can be identified and isolated from a cDNA or genomic library by conventional nucleic acid hybridization methods using a hybridization probe based on the nucleic acid sequences described herein. Other methods of isolating and cloning suitable Raf-encoding or Ras-encoding nucleic acids are readily apparent to one skilled in the art.

2. Expression Vectors

The invention contemplates a recombinant DNA molecule (rDNA) containing a DNA segment encoding a Raf and/or Ras protein as described herein. An

expressible rDNA can be produced by operatively (in frame, expressibly) linking a vector to a Raf or Ras encoding DNA segment of the present invention. It is envisioned that a combination expression can be constructed wherein Raf encoding and Ras encoding nucleic acid are present, either operably linked to the same, or separate promotors. Thus, a recombinant DNA molecule is a hybrid DNA molecule comprising at least two nucleic acids of a nucleotide sequences not normally found together in nature (i.e. gene and vector).

The choice of vector to which a DNA segment of the present invention is operatively linked depends directly, as is well known in the art, on the functional properties desired, e.g., protein expression, and the host cell to be transformed. Typical considerations in the art of constructing recombinant DNA molecules. A vector contemplated by the present invention is at least capable of directing the replication, and preferably also expression, of a structural gene included in the vector DNA segments, to which it is operatively linked.

Both prokaryotic and eukaryotic expression vectors are familiar to one of ordinary skill in the art of vector construction, and are described by Ausebel, et al., in Current Protocols in Molecular Biology, Wiley and Sons, New York (1993) and by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (1989). These references also describe many of the general recombinant DNA methods referred to herein.

In one embodiment, a vector contemplated by the present invention includes a procaryotic replicon, i.e., a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a procaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, those embodiments that include a procaryotic replicon also include a gene whose expression confers drug resistance to a bacterial host transformed therewith. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.

Those vectors that include a procaryotic replicon can also include a procaryotic promoter capable of directing the expression (transcription and translation) of a structural gene in a bacterial host cell, such as E. coli, transformed therewith. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoters or other such regulatory nucleic acid sequences can be inducible or constitutive depending upon the desired expression control and/or effect. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA), pRSET available from Invitrogen (San Diego, CA) and pPL and pKK223 available from Pharmacia, Piscataway, N.J.

Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can also be used to form the recombinant DNA molecules of the present invention. Eukaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC, #31255), pRc/CMV (Invitrogen, Inc.), the preferred vector described in the Examples, and the like eukaryotic expression vectors.

A particularly preferred system for gene expression in the context of this invention includes a gene delivery component, that is, the ability to deliver the gene to the tissue of interest. Suitable vectors are "infectious" vectors such as recombinant DNA viruses, adenovirus or retrovirus vectors which are engineered to express the desired protein and have features which allow infection of preselected target tissues. Particularly preferred is the retrovirus vector system described herein.

Mammalian cell systems that utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression

vectors, the coding sequence of a polypeptide may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted into the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the polypeptide in infected hosts (e.g., see Logan et al., Proc. Natl. Acad. Sci., USA, 81:3655-3659 (1984)). Alternatively, the vaccinia virus 7.5K promoter may be used (e.g., see, Mackett et al., Proc. Natl. Acad. Sci., USA, 79:7415-7419 (1982); Mackett et al., J. Virol., 49:857-864 (1984); Panicali et al., Proc. Natl. Acad. Sci., USA, 79:4927-4931 (1982)). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver et al., Mol. Cell. Biol., 1:486 (1981)). Shortly after entry of this DNA into target cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the neo gene. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of the polypeptide-encoding nucleotide sequence in host cells (Cone et al., Proc. Natl. Acad. Sci., USA, 81:6349-6353 (1984)). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine IIA promoter and heat shock promoters.

Recently, long-term survival of cytomegalovirus (CMV) promoter versus Rous sarcoma virus (RSV) promotor-driven thymidine kinase (TK) gene therapy in nude mice bearing human ovarian cancer has been studied. Cell killing efficacy of adenovirus-mediated CMV promoter-driven herpes simplex virus TK gene therapy was found to be 2 to 10 times more effective than RSV driven therapy (Tong et al., Hybridoma 18(1):93-97 (1999)). The design of chimeric promoters for gene therapy applications, which call for low level expression followed by inducible high-level

expression has also been described (Suzuki et al., Human Gene Therapy 7:1883-1893 (1996)).

For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with a cDNA controlled by appropriate expression control elements (e.g., promoter and enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. As mentioned above, the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.

For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell, 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska et al, Proc. Natl. Acad. Sci., USA, 48:2026 (1962)), and adenine phosphoribosyltransferase (Lowy et al., Cell, 22:817 (1980)) genes, which can be employed in tk^-, $hgprt^-$ or $aprt^-$ cells respectively. Also, antimetabolite resistance-conferring genes can be used as the basis of selection; for example, the genes for dhfr, which confers resistance to methotrexate (Wigler et al., Proc. Natl. Acad. Sci., USA, 77:3567 (1980); O'Hare et al., Proc. Natl. Acad. Sci., USA, 78:1527 (1981); gpt, which confers resistance to mycophenolic acid (Mulligan et al, Proc. Natl. Acad. Sci., USA, 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al, J. Mol. Biol., 150:1 (1981)); and hygro, which confers resistance to hygromycin (Santerre et al, Gene, 30:147 (1984)). Recently, additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman et al, Proc. Natl. Acad. Sci., USA, 85:804 (1988)); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO

(McConlogue L., In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed. (1987)).

The principal vectors contemplated for human gene therapy, are derived from retroviral origin (Wilson, Clin. Exp. Immunol. 107(Sup. 1):31-32 (1997); Bank et al., Bioessays 18(12):999-1007 (1996); Robbins et al., Pharmacol. Ther. 80(1):35-47 (1998)). The therapeutic potential of gene transfer and antisense therapy has stimulated the development of many vector systems for treating a variety of tissues (vasculature, Stephan et al., Fundam. Clin. Pharmacol. 11(2):97-110 (1997); Feldman et al., Cardiovasc. Res. 35(3):391-404 (1997); Vassalli et al., Cardiovasc. Res. 35(3):459-69 (1997); Baek et al., Circ. Res. 82(3):295-305 (1998); kidney, Lien et al., Kidney Int. Suppl. 61:S85-8 (1997); liver, Ferry et al., Hum Gene Ther. 9(14):1975-81 (1998); muscle, Marshall et al., Curr. Opn. Genet. Dev. 8(3):360-5 (1998)). In addition to these tissues, a critical target for human gene therapy is cancer, either the tumor itself, or associated tissues. (Runnebaum, Anticancer Res. 17(4B):2887-90 (1997); Spear et al., J. Neurovirol. 4(2):133-47 (1998)).

Specific examples of viral gene therapy vector systems readily adaptable for use in the methods of the present invention are briefly described below. Retroviral gene delivery has been recently reviewed by Federspiel and Hughes (Methods in Cell Biol. 52:179-214 (1998)) which describes in particular, the avian leukosis virus (ALV) retrovirus family (Federspiel et al., Proc. Natl. Acad. Sci., USA, 93:4931 (1996); Federspiel et al., Proc. Natl. Acad. Sci., USA, 91:11241 (1994)). Retroviral vectors, including ALV and murine leukemia virus (MLV) are further described by Svoboda (Gene 206:153-163 (1998)).

Modified retroviral/adenoviral expression systems can be readily adapted for practice of the methods of the present invention. For example, murine leukemia virus (MLV) systems are reviewed by Karavanas et al., Crit. Rev. in Oncology/Hematology 28:7-30 (1998). Adenovirus expression systems are reviewed by Von Seggern and Nemerow in Gene Expression Systems (ed. Fernandez & Hoeffler, Academic Press, San Diego, CA, chapter 5, pages 112-157 (1999)).

Protein expression systems have been demonstrated to have effective use both *in vivo* and *in vitro*. For example, efficient gene transfer to human squamous cell carcinomas by a herpes simplex virus (HSV) type 1 amplicon vector has been described. (Carew et al., 1998, Am. J. Surg. 176:404-408). Herpes simplex virus has been used for gene transfer to the nervous system (Goins et al., J. Neurovirol. 3 (Sup. 1):S80-8 (1997)). Targeted suicide vectors using HSV-TK has been tested on solid tumors (Smiley et al., Hum. Gene Ther. 8(8):965-77 (1997)). Herpes simplex virus type 1 vector has been used for cancer gene therapy on colon carcinoma cells (Yoon et al., Ann. Surg. 228(3):366-74 (1998)). Hybrid vectors have been developed to extend the length of time of transfection, including HSV/AAV (adeno-associated virus) hybrids for treating hepatocytes (Fraefel et al., Mol. Med. 3(12):813-825 (1997)).

Vaccinia virus has been developed for human gene therapy because of its large genome (Peplinski et al., Surg. Oncol. Clin. N. Am. 7(3):575-88 (1998)). Thymidine kinase-deleted vaccinia virus expressing purine nucleoside pyrophosphorylase has been described for use as a tumor directed gene therapy vector. (Puhlman et al., Human Gene Therapy 10:649-657 (1999)).

Adeno-associated virus 2 (AAV) has been described for use in human gene therapy, however AAV requires a helper virus (such as adenovirus or herpes virus) for optimal replication and packaging in mammalian cells (Snoeck et al., Exp. Nephrol. 5(6):514-20 (1997); Rabinowitz et al., Curr. Opn. Biotechnol. 9(5):470-5 (1998)). However, *in vitro* packaging of an infectious recombinant AAV has been described, making this system much more promising (Ding et al., Gene Therapy 4:1167-1172 (1997)). It has been shown that the AAV mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells (Qing et al., J. Virology 71(7):5663-5667 (1997)). Cancer gene therapy using an AAV vector expressing human wild-type p53 has been demonstrated (Qazilbash et al., Gene Therapy 4:675-682 (1997)). Gene transfer into vascular cells using AAV vectors has also been shown (Maeda et al., Cardiovascular Res. 35:514-521 (1997)). AAV has been demonstrated as a suitable vector for liver directed gene

therapy (Xiao et al., J. Virol. 72(12):10222-6 (1998)). AAV vectors have been demonstrated for use in gene therapy of brain tissues and the central nervous system (Chamberlin et al., Brain Res. 793(1-2):169-75 (1998); During et al., Gene Therapy 5(6):820-7 (1998)). AAV vectors have also been compared with adenovirus vectors (AdV) for gene therapy of the lung and transfer to human cystic fibrosis epithelial cells (Teramoto et al., J. Virol. 72(11):8904-12 (1998)).

Chimeric AdV/retroviral gene therapy vector systems which incorporate the useful qualities of each virus to create a nonintegrative AdV that is rendered functionally integrative via the intermediate generation of a retroviral producer cell (Feng et al., Nat. Biotechnology 15(9):866-70 (1997); Bilbao et al., FASEB J 11(8):624-34 (1997)). This powerful new generation of gene therapy vector has been adapted for targeted cancer gene therapy (Bilbao et al., Adv. Exp. Med. Biol. 451:365-74 (1998)). Single injection of AdV expressing p53 inhibited growth of subcutaneous tumor nodules of human prostrate cancer cells (Asgari et al., Int. J. Cancer 71(3):377-82 (1997)). AdV mediated gene transfer of wild-type p53 in patients with advanced non-small cell lung cancer has been described (Schuler et al., Human Gene Therapy 9:2075-2082 (1998)). This same cancer has been the subject of p53 gene replacement therapy mediated by AdV vectors (Roth et al., Semin. Oncol. 25(3 Suppl 8):33-7 (1998)). AdV mediated gene transfer of p53 inhibits endothelial cell differentiation and angiogenesis *in vivo* (Riccioni et al., Gene Ther. 5(6):747-54 (1998)). Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma has also been described (Hirschowitz et al., Gene Therapy 5:975-983 (1998)). AdV facilitates infection of human cells with ecotropic retrovirus and increases efficiency of retroviral infection (Scott-Taylor, et al., Gene Ther. 5(5):621-9 (1998)). AdV vectors have been used for gene transfer to vascular smooth muscle cells (Li et al., Chin. Med. J.(Engl) 110(12):950-4 (1997)), squamous cell carcinoma cells (Goebel et al., Otolarynol Head Neck Surg 119(4):331-6 (1998)), esophageal cancer cells (Senmaru et al., Int J. Cancer 78(3):366-71 (1998)), mesangial cells (Nahman et al., J. Investig. Med. 46(5):204-9 (1998)), glial cells (Chen et al.,

Cancer Res. 58(16):3504-7 (1998)), and to the joints of animals (Ikeda et al., J. Rheumatol. 25(9):1666-73 (1998)). More recently, catheter-based pericardial gene transfer mediated by AcV vectors has been demonstrated (March et al., Clin. Cardiol. 22(1 Suppl 1):I23-9 (1999)). Manipulation of the AdV system with the proper controlling genetic elements allows for the AdV-mediated regulatable target gene expression *in vivo* (Burcin et al., PNAS (USA) 96(2):355-60 (1999)).

Alphavirus vectors have been developed for human gene therapy applications, with packaging cell lines suitable for transformation with expression cassettes suitable for use with Sindbis virus and Semliki Forest virus-derived vectors (Polo et al., Proc. Natl. Acad. Sci., USA, 96:4598-4603 (1999)). Noncytopathic flavivirus replicon RNA-based systems have also been developed (Varnavski et al., Virology 255(2):366-75 (1999)). Suicide HSV-TK gene containing sinbis virus vectors have been used for cell-specific targeting into tumor cells (Iijima et al., Int. J. Cancer 80(1):110-8 (1998)).

Retroviral vectors based on human foamy virus (HFV) also show promise as gene therapy vectors (Trowbridge et al., Human Gene Therapy 9:2517-2525 (1998)). Foamy virus vectors have been designed for suicide gene therapy (Nestler et al., Gene Ther. 4(11):1270-7 (1997)). Recombinant murine cytomegalovirus and promoter systems have also been used as vectors for high level expression (Manning et al., J. Virol. Meth. 73(1):31-9 (1998); Tong et al., Hybridoma 18(1):93-7 (1998)).

Gene delivery into non-dividing cells has been made feasible by the generation of Sendai virus based vectors (Nakanishi et al., J. Controlled Release 54(1):61-8 (1998)).

In other efforts to enable the transformation of non-dividing somatic cells, lentiviral vectors have been explored. Gene therapy of cystic fibrosis using a replication-defective human immunodeficiency virus (HIV) based vector has been described. (Goldman et al., Human Gene Therapy 8:2261-2268 (1997)). Sustained expression of genes delivered into liver and muscle by lentiviral vectors has also been shown (Kafri et al., Nat. Genet. 17(3):314-7 (1997)). However, safety concerns are predominant, and improved vector development is proceeding rapidly (Kim et al., J.

Virol. 72(2):994-1004 (1998)). Examination of the HIV LTR and Tat yield important information about the organization of the genome for developing vectors (Sadaie et al., J. Med. Virol. 54(2):118-28 (1998)). Thus, the genetic requirements for an effective HIV based vector are now better understood (Gasmi et al., J. Virol. 73(3):1828-34 (1999)). Self inactivating vectors, or conditional packaging cell lines have been described (for example, Zuffery et al., J. Virol. 72(12):9873-80 (1998); Miyoshi et al., J. Virol. 72(10):8150-7 (1998); Dull et al., J. Virol. 72(11):8463-71 (1998); and Kaul et al., Virology 249(1):167-74 (1998)). Efficient transduction of human lymphocytes and CD34+ cells by HIV vectors has been shown (Douglas et al., Hum. Gene Ther. 10(6):935-45 (1999); Miyoshi et al., Science 283(5402):682-6 (1999)). Efficient transduction of nondividing human cells by feline immunodeficiency virus (FIV) lentiviral vectors has been described, which minimizes safety concerns with using HIV based vectors (Poeschla et al., Nature Medicine 4(3):354-357 (1998)). Productive infection of human blood mononuclear cells by FIV vectors has been shown (Johnston et al., J. Virol. 73(3):2491-8 (1999)).

While many viral vectors are difficult to handle, and capacity for inserted DNA limited, these limitations and disadvantages have been addressed. For example, in addition to simplified viral packaging cell lines, Mini-viral vectors, derived from human herpes virus, herpes simplex virus type 1 (HSV-1), and Epstein-Barr virus (EBV), have been developed to simplify manipulation of genetic material and generation of viral vectors (Wang et al., J. Virology 70(12):8422-8430 (1996)). Adaptor plasmids have been previously shown to simplify insertion of foreign DNA into helper-independent Retroviral vectors (J. Virology 61(10):3004-3012 (1987)).

Viral vectors are not the only means for effecting gene therapy, as several non-viral vectors have also been described. A targeted non-viral gene delivery vector based on the use of Epidermal Growth Factor/DNA polyplex (EGF/DNA) has been shown to result in efficient and specific gene delivery (Cristiano, Anticancer Res. 18:3241-3246 (1998)). Gene therapy of the vasculature and CNS have been demonstrated using cationic liposomes (Yang et al., J. Neurotrauma 14(5):281-97

(1997)). Transient gene therapy of pancreatitis has also been accomplished using cationic liposomes (Denham et al., Ann. Surg. 227(6):812-20 (1998)). A chitosan-based vector/DNA complexes for gene delivery have been shown to be effective (Erbacher et al., Pharm. Res. 15(9):1332-9 (1998)). A non-viral DNA delivery vector based on a terplex system has been described (Kim et al., 53(1-3):175-82 (1998)). Virus particle coated liposome complexes have also been used to effect gene transfer (Hirai et al., Biochem. Biophys. Res. Commun. 241(1):112-8 (1997)).

Cancer gene therapy by direct tumor injections of nonviral T7 vector encoding a thymidine kinase gene has been demonstrated (Chen et al., Human Gene Therapy 9:729-736 (1998)). Plasmid DNA preparation is important for direct injection gene transfer (Horn et al., Hum. Gene Ther. 6(5):656-73 (1995)). Modified plasmid vectors have been adapted specifically for direct injection (Hartikka et al., Hum. Gene Ther. 7(10):1205-17 (1996)).

Thus, a wide variety of gene transfer/gene therapy vectors and constructs are known in the art. These vectors are readily adapted for use in the methods of the present invention. By the appropriate manipulation using recombinant DNA/molecular biology techniques to insert an operatively linked Raf or Ras encoding nucleic acid segment (either active or inactive) into the selected expression/delivery vector, many equivalent vectors for the practice of the present invention can be generated.

F. Methods For Modulation of Angiogenesis

In one aspect, the present invention provides for a method for the modulation of angiogenesis in a tissue associated with a disease process or condition, and thereby affect events in the tissue which depend upon angiogenesis. Generally, the method comprises administering to the tissue, associated with, or suffering from a disease process or condition, an angiogenesis-modulating amount of a composition comprising a Raf protein or a nucleic acid vector expressing active or inactive Raf.

A further method comprises administering to the tissue, associated with a disease process or condition, an angiogenesis-modulating amount of a composition comprising a Ras protein or a nucleic acid vector expressing active or inactive Ras. Another method aspect comprises administering to the tissue associated with a disease process or condition, an angiogenesis-modulating amount of a Raf and Ras protein or one or more nucleic acid vector expressing active or inactive Raf and Ras.

Any of a variety of tissues, or organs comprised of organized tissues, can support angiogenesis in disease conditions including skin, muscle, gut, connective tissue, brain tissue, nerve cells, joints, bones and the like tissue in which blood vessels can invade upon angiogenic stimuli.

The patient to be treated according to the present invention in its many embodiments is a human patient, although the invention is effective with respect to all mammals. In this context, a "patient" is a human patient as well as a vetrinary patient, a mammal of any mammalian species in which treatment of tissue associated with diseases involving angiogenesis is desirable, particularly agricultural and domestic mammalian species.

Thus, the method embodying the present invention comprises administering to a patient a therapeutically effective amount of a physiologically tolerable composition containing a Raf and/or Ras protein or nucleic acid vector for expressing a Raf and/or Ras protein.

The dosage ranges for the administration of a Raf or Ras protein depend upon the form of the protein, and its potency, as described further herein, and are amounts large enough to produce the desired effect in which angiogenesis and the disease symptoms mediated by angiogenesis are ameliorated. The dosage should not be so large as to cause adverse side effects, such as hyperviscosity syndromes, pulmonary edema, congestive heart failure, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can also be adjusted by the individual physician in the event of any complication.

A therapeutically effective amount is an amount of Raf or Ras protein, or nucleic acid encoding for (active or inactive) Raf or Ras protein, sufficient to produce a measurable modulation of angiogenesis in the tissue being treated, i.e., an angiogenesis-modulating amount. Modulation of angiogenesis can be measured or monitored *in vitro* by CAM assay as described herein, examination of tumor tissues, or by other methods known to one skilled in the art.

The Raf or Ras protein or nucleic acid vector expressing such protein can be administered parenterally by injection or by gradual infusion over time. Although the tissue to be treated can typically be accessed in the body by systemic administration and therefore most often treated by intravenous administration of therapeutic compositions, other tissues and delivery means are contemplated where there is a likelihood that the tissue targeted contains the target molecule. Thus, compositions of the invention can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, and can be delivered by peristaltic means, if desired.

The therapeutic compositions containing a Raf or Ras protein or nucleic acid vector expressing the Raf or Ras protein can be conventionally administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required physiologically acceptable diluent; i.e., carrier, or vehicle.

In one preferred embodiment the active material is administered in a single dosage intravenously. Localized administration can be accomplished by direct injection or by taking advantage of anatomically isolated compartments, isolating the microcirculation of target organ systems, reperfusion in a circulating system, or catheter based temporary occlusion of target regions of vasculature associated with diseased tissues.

The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered and timing depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations in the blood in the ranges specified for *in vivo* therapies are contemplated.

1. Inhibition of Angiogenesis

There are a variety of diseases in which inhibition of angiogenesis is important, referred to as angiogenic diseases, including but not limited to, inflammatory disorders such as immune and non-immune inflammation, chronic articular rheumatism and psoriasis, disorders associated with inappropriate or inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma, restenosis, capillary proliferation in atherosclerotic plaques and osteoporosis, and cancer associated disorders, such as solid tumors, solid tumor metastases, angiofibromas, retrolental fibroplasia, hemangiomas, Kaposi sarcoma and the like cancers which require neovascularization to support tumor growth.

Thus, methods which inhibit angiogenesis in a tissue associated with a disease condition ameliorates symptoms of the disease and, depending upon the disease, can contribute to cure of the disease. In one embodiment, the invention contemplates inhibition of angiogenesis, per se, in a tissue associated with a disease condition. The extent of angiogenesis in a tissue, and therefore the extent of inhibition achieved by the present methods, can be evaluated by a variety of methods.

Thus, in one embodiment, a tissue to be treated is an inflamed tissue and the angiogenesis to be inhibited is inflamed tissue angiogenesis where there is neovascularization of inflamed tissue. This particular method includes inhibition of angiogenesis in arthritic tissues, such as in a patient with chronic articular rheumatism, in immune or non-immune inflamed tissues, in psoriatic tissue, and the like.

In another embodiment, a tissue to be treated is a retinal tissue of a patient suffering from a retinal disease such as diabetic retinopathy, macular degeneration or neovascular glaucoma and the angiogenesis to be inhibited is retinal tissue angiogenesis where there is neovascularization of retinal tissue.

In an additional embodiment, a tissue to be treated is a tumor tissue of a patient with a solid tumor, a metastases, a skin cancer, a breast cancer, a hemangioma or angiofibroma and the like cancer, and the angiogenesis to be inhibited is tumor tissue angiogenesis where there is neovascularization of a tumor tissue. Typical solid tumor tissues treatable by the present methods include lung, pancreas, breast, colon, laryngeal, ovarian, and the like tissues. Inhibition of tumor tissue angiogenesis is a particularly preferred embodiment because of the important role neovascularization plays in tumor growth. In the absence of neovascularization of tumor tissue, the tumor tissue does not obtain the required nutrients, slows in growth, ceases additional growth, regresses and ultimately becomes necrotic resulting in killing of the tumor.

Stated in other words, the present invention provides for a method of inhibiting tumor neovascularization by inhibiting tumor angiogenesis according to the present methods. Similarly, the invention provides a method of inhibiting tumor growth by practicing the angiogenesis-inhibiting methods.

The methods are also particularly effective against the formation of metastases because (1) their formation requires vascularization of a primary tumor so that the metastatic cancer cells can exit the primary tumor and (2) their establishment in a secondary site requires neovascularization to support growth of the metastases.

In a yet further embodiment, the invention contemplates the practice of the method in conjunction with other therapies such as conventional chemotherapy

directed against solid tumors and for control of establishment of metastases. The administration of angiogenesis inhibitor is typically conducted during or after chemotherapy, although it is preferably to inhibit angiogenesis after a regimen of chemotherapy at times where the tumor tissue will be responding to the toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. In addition, it is preferred to administer the angiogenesis inhibition methods after surgery where solid tumors have been removed as a prophylaxis against metastases.

Insofar as the present methods apply to inhibition of tumor neovascularization, the methods can also apply to inhibition of tumor tissue growth, to inhibition of tumor metastases formation, and to regression of established tumors.

Restenosis is a process of smooth muscle cell (SMC) migration and proliferation into the tissue at the site of percutaneous transluminal coronary angioplasty which hampers the success of angioplasty. The migration and proliferation of SMC's during restenosis can be considered a process of angiogenesis which is inhibited by the present methods. Therefore, the invention also contemplates inhibition of restenosis by inhibiting angiogenesis according to the present methods in a patient following angioplasty procedures. For inhibition of restenosis, the inactivated tyrosine kinase is typically administered after the angioplasty procedure because the coronary vessel wall is at risk of restenosis, typically for from about 2 to about 28 days, and more typically for about the first 14 days following the procedure.

The present method for inhibiting angiogenesis in a tissue associated with a disease condition, and therefore for also practicing the methods for treatment of angiogenesis-related diseases, comprises contacting a tissue in which angiogenesis is occurring, or is at risk for occurring, with a therapeutically effective amount of a composition comprising an inactivated Raf protein or vector expressing the protein. Inhibition of angiogenesis and tumor regression occurs as early as 7 days after the initial contacting with the therapeutic composition. Additional or prolonged exposure to inactive Raf or Ras protein is preferable for 7 days to 6 weeks, preferably about 14

to 28 days. Shorter periods of exposure can be useful where the modulating effects are detectable earlier, however administration and subsequent exposure for at least 12 hours is preferred.

2. Potentiation of Angiogenesis

In cases where it is desirable to promote or potentiate angiogenesis, administration of an active Raf or Ras protein to the tissue is useful. The routes and timing of administration are comparable to the methods described hereinabove for inhibition.

G. Therapeutic Compositions

The present invention contemplates therapeutic compositions useful for practicing the therapeutic methods described herein. Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with a Raf or Ras protein or vector capable of expressing a Raf or Ras protein as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.

As used herein, the terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation. Typically such compositions are prepared as injectable either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified or presented as a liposome composition.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

A therapeutic composition contains an angiogenesis-modulating amount of a Raf or Ras protein of the present invention, or sufficient recombinant DNA expression vector to express an effective amount of Raf or Ras protein, typically formulated to

contain an amount of at least 0.1 weight percent of Raf or Ras protein per weight of total therapeutic composition. A weight percent is a ratio by weight of Raf protein to total composition. Thus, for example, 0.1 weight percent is 0.1 grams of Raf or Ras protein per 100 grams of total composition. For DNA expression vectors, the amount administered depends on the properties of the expression vector, the tissue to be treated, and the like considerations. The suitable amount administered can be measured by amount of vector, or amount of expressed protein that is expected.

H. Article of Manufacture

The invention also contemplates an article of manufacture which is a labeled container for providing a Raf or Ras protein of the invention. An article of manufacture comprises packaging material and a pharmaceutical agent contained within the packaging material.

The pharmaceutical agent in an article of manufacture is any of the compositions of the present invention suitable for providing a Raf or Ras protein and formulated into a pharmaceutically acceptable form as described herein according to the disclosed indications. Thus, the composition can comprise a Raf and/or Ras protein or a DNA molecule which is capable of expressing a Raf and/or Ras protein. The article of manufacture contains an amount of pharmaceutical agent sufficient for use in treating a condition indicated herein, either in unit or multiple dosages.

The packaging material comprises a label which indicates the use of the pharmaceutical agent contained therein, e.g., for treating conditions assisted by the inhibition or potentiation of angiogenesis, and the like conditions disclosed herein. The label can further include instructions for use and related information as may be required for marketing. The packaging material can include container(s) for storage of the pharmaceutical agent.

As used herein, the term packaging material refers to a material such as glass, plastic, paper, foil, and the like capable of holding within fixed means a pharmaceutical agent. Thus, for example, the packaging material can be plastic or

glass vials, laminated envelopes and the like containers used to contain a pharmaceutical composition including the pharmaceutical agent.

In preferred embodiments, the packaging material includes a label that is a tangible expression describing the contents of the article of manufacture and the use of the pharmaceutical agent contained therein.

Examples

The following examples relating to this invention are illustrative and should not, of course, be construed as specifically limiting the invention. Moreover, such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are to be considered to fall within the scope of the present invention hereinafter claimed.

1. Preparation of c-Raf Expression Constructs

For preparing the expression constructs useful in modulating angiogenesis by the methods of the present invention, c-Raf cDNA is manipulated and inserted into an expression construct/vector.

The cDNA sequence encoding for wild-type (i.e., endogenous) human c-Raf is depicted in the nucleic acid sequence shown in FIG. 7 (SEQ ID NO.: 1, nucleotides 130...2076) with the encoded translated amino acid residue sequence for the Raf protein depicted in FIG. 8 (SEQ ID NO.: 2).

The present invention describes two categories of c-Raf function to modulate angiogenesis. As previously discussed, one category contains Raf molecules that increase angiogenesis and, thus, are considered to be active proteins. Wild-type Raf along with various mutations are shown in the present invention to induce angiogenesis.

One preferred mutation of wild type c-Raf which functions in this context with respect to its ability to induce blood vessel growth and therefore increase tumor weight *in vivo* is the Raf mutant construct in which only the amino acid residues 306-648 of

Raf (Raf 306-648) are expressed. This construct lacks the entire regulatory kinase domain and is therefore referred to as a constitutively active Raf protein.

Mutations in Raf have also been shown to have the opposite modulatory effect on angiogenesis, inhibiting angiogenesis instead of stimulating it. Such mutations are referred to as inactive Raf mutations. Proteins having mutations that confer this inhibitory activity are also referred to as dominant negative Raf proteins in that they inhibit neovascularization, including that resulting from endogenous activity of Raf as well as enhanced Raf activity resulting from growth factor stimulation. Thus, certain mutations of wild type c-Raf of the present invention can also function as a dominant negative with respect to their ability to block blood vessel growth, and for example, therefore decrease tumor weight *in vivo*.

An exemplary inhibitory Raf construct is the Raf mutation in which the lysine amino acid residue 375 is mutated into any other amino acid, preferably a methionine (i.e., Raf K375M). This point mutation in the kinase domain prevents ATP binding and also blocks kinase-dependent Raf functions related to vascular cell and tumor cell signaling and proliferation. Another inhibitory Raf mutant would comprise amino acid residues 1-305 in the form of a truncated Raf protein (i.e., Raf 1-305), which lacks the kinase domain.

With respect to the point mutations, any mutation resulting in the desired inhibitory or stimulatory activity is contemplated for use in this invention. Fusion protein constructs combining the desired Raf protein (mutation or fragment thereof) with expressed amino acid tags, antigenic epitopes, fluorescent protein, or other such protein or peptides are also contemplated, so long as the desired modulating effect of the Raf protein is intact.

To produce the desired c-Raf mutations in the cDNA, standard site-directed mutagenesis procedures familiar to one of ordinary skill in the art were utilized. PCR primers designed to incorporate the desired mutations were also designed with restriction sites to facilitate subsequent cloning steps. Entire segments of Raf encoding nucleic acid sequences are deleted from the nucleic acid constructs through

PCR amplification techniques based on the known cDNA sequences of chicken, human and the like homologs of Raf and subsequent formation of new constructs.

Specifically, the wild-type Raf cDNA sequence shown in FIG. 7 was modified in several ways to construct Raf mutants to demonstrate the principles of the present invention. These mutants were inserted into the retrovirus expression system described herein.

A first mutant Raf, designated Raf K375M, was constructed in wild-type human Raf in which lysine at amino acid residue position 375 was substituted by a methionine. Raf K375M is an "inactive" Raf protein as defined herein.

A second mutant Raf, designated Raf 306-648, was constructed in wild-type human Raf in which the amino terminal portion was deleted, leaving the truncated carboxy terminal residues 306-648. Raf 306-648 is an "active" Raf protein as defined herein.

A third mutant Raf, designated Raf 1-305, is constructed in wild type human Raf in which the carboxy terminal portion was deleted, leaving the truncated amino terminal residues 1-305. Raf 1-305 is an "inactive" Raf protein as defined herein.

Alternative expression vectors for use in the expressing the Raf or Ras proteins of the present invention also include adenoviral vectors as described in US Patent No. 4,797,368, No. 5,173,414, No. 5,436,146, No. 5,589,377, and No. 5,670,488. Alternative methods for the delivery of the Raf or Ras modulatory proteins include delivery of the Raf or Ras cDNA with a non-viral vector system as described in US Patent No. 5,675,954 and delivery of the cDNA itself as naked DNA as described in US Patent No. 5,589,466. Delivery of constructs of this invention is also not limited to topical application of a viral vector, viral vector preparations are also injected intravenously for systemic delivery into the vascular bed, or can be injected subcutaneously, intratissue, and the like. These vectors are also targetable to sites of increased neovascularization by localized injection of a tumor, as an example.

In vitro expressed proteins are also contemplated for delivery thereof following expression and purification of the selected Raf or Ras protein by methods useful for

delivery of proteins or polypeptides. One such method includes liposome delivery systems, such as described in US Patent No. 4,356,167, No. 5,580,575, No. 5,542,935 and No. 5,643,599. Other vector and protein delivery systems are well known to those of ordinary skill in the art for use in the expression and/or delivery of the Raf or Ras proteins of the present invention.

2. Human Tumor Model

To demonstrate the efficacy of the present invention, human tumor cells were implanted subcutaneously onto the flank of athymic mice, and allowed to grow to about 100 mm^3. In this xenograft model, the murine endothelial cells in the tissue surrounding the implant form vasculature that grow into the growing human tumor in response to the normal angiogenic signals, and the tumor becomes vascularized. Thus, the microvessels are formed by murine endothelial cells, whereas the tumor tissue itself comprises human cells.

3. Retrovirus Delivery Vector Infects Mouse Lineage Cells, Not Human Tumor Cells

The retrovirus expression vector system of Clonetech was used to construct ecotrophic retrovirus which contain the constructs of Raf described herein. To demonstrate the tissue specificity of the infecting retrovirus, a retrovirus expression vector construct which expresses b-galactosidase was packaged using ecotrophic packaging cells as described in the legend to FIG. 1.

Mouse 3T3, mouse endothelial cells, human epithelial adenocarcinoma LS174 cells and human melanoma M21 cells were cultured *in vitro*, and were each exposed to the ecotrophically packaged retrovirus. Only the murine cells express detectable b-galactosidase, indicating that only murine cells are infected by ecotrophically packaged retrovirus in this expression system.

4. Inactive Raf Kinase Disrupts Raf Kinase Activity In Vitro

To demonstrate the cellular effects of inactive Raf kinase, an *in vitro* model using mouse endothelial cells induced by bFGF was used. The normal induction of Raf activity by bFGF administration to mouse endothelial cells was blocked when those cells were first infected by a retroviral construct which expressed the inactive Raf K375M kinase construct as described in the legend to FIG. 2. The data in FIG. 2 shows that the amount of Raf kinase activity is substantially reduced when cells are first infected by the vector which expresses an inactive Raf kinase.

5. Inactive Raf Kinase Disrupts Angiogenesis In Vivo

Using an *in vivo* murine subcutaneous model for angiogenesis, the effects of inactive Raf kinase were studied. To that end, angiogenesis was induced in a mouse by injection of bFGF either with or without cells expressing retrovirus that produces the inactive Raf K375M kinase protein as described in the legend to FIG. 3. As shown in FIG. 3, the presence of inactive Raf kinase substantially reduced the angiogenic index.

6. Active Raf Kinase Induces Angiogenesis In Vivo

Using the murine subcutaneous model for angiogenesis, the effects of active Raf kinase were studied. To that end, angiogenesis was induced by injection of cells expressing retrovirus that produced the active Raf 306-648 kinase as described in the legend to FIG. 4. As shown in FIG. 4, mutationally active Raf kinase induces angiogenesis *in vivo*.

7. Inactive Raf Kinase Induces Apoptosis

Using the mouse xenograft model described above, the *in vivo* effects of inactive Raf were studied. To that end, the model was established as described in the legend to FIG. 5 by injection of 1.5 million human adenocarcinoma LS174 cells. Following establishment of a tumor mass of about 100 mm^3, retrovirus expressing the inactive Raf K375M kinase were injected into the tumor mass, and

immunohistochemistry was performed on sections of the tumor mass after 48 hours. The results shown in FIG. 5 (Flag tag) indicate that the retrovirus infection was endothelial specific, and further shows via the vWF stain that the endothelial cells colocalized to the retrovirus infection. The merge of the staining data shows that the endothelial cells, the virus infection and the occurrence of apoptosis all colocalized, indicating that the virus delivery of the inactive Raf protein is endothelial specific and that inactive Raf induces apoptosis.

8. Inactive Raf Kinase Induces Tumor Regression

Using the mouse xenograft model described above, the *in vivo* effects of inactive Raf on tumor regression were studied. To that end, the model was established as described in the legend to FIG. 6, and the inactive Raf K375M kinase was provided as virus supernate or virus-expressing cells as indicated. The established tumor was seen to rapidly regress upon introduction of inactive Raf kinase.

9. Angiogenesis is Dependent on Activation of the Ras-Raf-MEK-ERK Pathway

To determine the interaction of growth factor receptor and integrin receptor ligation and activation on the activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) cascade that is involved in modulating angiogenesis, the following studies in Examples 9-11 were performed. Activation of the MAPK cascade by integrin-mediated cell adhesion has been investigated by a number of laboratories as reviewed by Aplin et al., Pharmacol. Rev., 50:197-263 (1998). The hierarchical ERK cascade originates at the cell membrane with receptors for mitogens and growth factors which recruits the small guanosine triphosphate (GTPase) Ras which then activates Raf, a protein kinase, by binding to Raf and recruiting it to the membrane, where it is activated in a yet undetermined mechanism. Activated Raf then phosphorylates and activates MEK (MAPK/ERK kinase). MEK, then, phosphorylates and activates ERK1 and ERK2 which then translocate to the nucleus and transactivate transcription factors to effect growth,

differentiation or mitosis through altered gene expression. (See, Tibbles et al., Cell Mol. Life Sci., 55:1230-1254 (1999)).

The upstream regulation of Ras in activation of Raf that is mediated by growth factor and/or integrin signaling is the subject of current studies but the mechanisms of signaling are still not completely understood. (See, Stewart et al., J. Biol. Chem., 275:8854-8862 (2000); Howe et al., J. Biol. Chem., 273:27268-27274 (1998)). However, and more importantly, the activation of the Ras-Raf-MEK-ERK cascade through cell membrane receptor signaling resulting in modulation of angiogenesis has not been described before the present invention.

A. Ras is Induced by Exposure to bFGF

Therefore, to first assess whether angiogenesis was dependent on the Ras-Raf-MEK-ERK pathway, Ras activity was measured in chick chorioallantoic membrane (CAM) lysates exposed to bFGF as determined by a Ras pulldown assay.

Angiogenesis can be induced on the CAM after normal embryonic angiogenesis has resulted in the formation of mature blood vessels. Angiogenesis has been shown to be induced in response to specific cytokines or tumor fragments as described by Leibovich et al., Nature, 329:630 (1987) and Ausprunk et al., Am. J. Pathol., 79:597 (1975). CAMs were prepared from chick embryos for subsequent induction of angiogenesis and inhibition thereof. Ten day old chick embryos were obtained from McIntyre Poultry (Lakeside, CA) and incubated at 37°C with 60% humidity. A small hole was made through the shell at the end of the egg directly over the air sac with the use of a small crafts drill (Dremel, Division of Emerson Electric Co. Racine WI). A second hole was drilled on the broad side of the egg in a region devoid of embryonic blood vessels determined previously by candling the egg. Negative pressure was applied to the original hole, which resulted in the CAM (chorioallantoic membrane) pulling away from the shell membrane and creating a false air sac over the CAM. A 1.0 centimeter (cm) x 1.0 cm square window was cut

through the shell over the dropped CAM with the use of a small model grinding wheel (Dremel). The small window allowed direct access to the underlying CAM.

The resultant CAM preparation was then used at 10 days of embryogenesis where angiogenesis has subsided. The latter preparation was, thus, used in this invention for inducing renewed angiogenesis in response to cytokine treatment or tumor contact, where necessary, as described below.

1) Angiogenesis Induced by Growth Factors

Angiogenesis has been shown to be induced by cytokines or growth factors. Angiogenesis was induced by placing a 5 millimeter (mm) X 5 mm Whatman filter disk (Whatman Filter paper No.1) saturated with Hanks Balanced Salt Solution (HBSS, GIBCO, Grand Island, NY) or HBSS containing recombinant basic fibroblast growth factor (bFGF) or vascular endothelial cell growth factor (VEGF) (Genzyme, Cambridge, MA) on the CAM of either a 9 or 10 day chick embryo in a region devoid of blood vessels and the windows were latter sealed with tape. Other growth factors are also effective at inducing blood vessel growth. For assays where inhibition of angiogenesis is evaluated with intravenous injections of antagonists, such as LM609 monoclonal antibody, angiogenesis is first induced with bFGF or VEGF in fibroblast growth medium, and then inhibitors are administered as described in Example 10. Angiogenesis was monitored by photomicroscopy after 72 hours.

CAMs from 10-day old chick embryos were stimulated topically with filter disks saturated with either PBS or 30 nanograms (ng) of bFGF. After 5 minutes, CAM tissue was resected, homogenized in lysis buffer, and Ras activity was then determined by its capacity to be precipitated by a GST fusion peptide encoding the Ras binding domain of Raf. Because only active Ras binds Raf, a recombinant protein was generated consisting of the Ras binding domain of Raf conjugated to glutathione-S-transferase (GST). In turn GST was conjugated to sepharose beads enabling the precipitation of active Ras from a tissue lysate.

The results are shown in FIG. 9 where Ras activity was elevated in CAM lysates exposed to bFGF as determined by a Ras pulldown assay. Thus, Ras is induced with exposure to bFGF in the CAM. The role of Ras in the formation of angiogenic blood vessels in the CAM is further assessed as described in Example 10.

B. Ras is Necessary for Angiogenesis

To then determine whether angiogenesis was dependent on the activation of Ras in the CAM preparation, the CAM was exposed to RCAS retroviral preparations for expression of a dominant negative Ras mutant, S17N Ras, in combination with bFGF activation of Ras as described below. This mutant has been shown to bind GDP with preferential affinity over GTP, thereby providing the mutant to inhibit endogenous Ras activation by sequestering Ras-GEFs. Thus, use of the mutant in the CAM angiogenesis model provides a method to assess the role of Ras in angiogenesis.

The S17N Ras mutant is created from the wild -type human Ras (wt H-Ras) sequence by standard site directed mutagenesis procedures as previously described substituting the encoding triplet for a serine (S) residue at position 17 with a codon for encoding an asparagine (N). Such mutants have been described by others, for example, by Stewart et al., J. Biol. Chem., 275:8854-8862 (2000).

To prepare the retroviral construct of the dominant negative expression construct, such mutagenesis was performed on the wt H-Ras, where the nucleic acid sequence encoding it is shown in FIG. 10 (SEQ ID NO.: 3). FIG. 11 (SEQ ID NO.: 4) depicts the amino acid residue sequence encoded by the cDNA nucleotide sequence of wild-type human Ras (wt H-Ras) shown in FIG. 10. To produce the desired mutations in the wt H-Ras cDNA to make S17N Ras as well as those described below, standard site-directed mutagenesis procedures familiar to one of ordinary skill in the art were utilized. PCR primers designed to incorporate the desired mutations were also designed with restriction sites to facilitate subsequent cloning steps. Entire segments of Ras encoding nucleic acid sequences can be deleted from the nucleic acid constructs

through PCR amplification techniques based on the known cDNA sequences of chicken, human and the like homologs of Ras and subsequent formation of new constructs. All mutant constructs constructed by PCR were also sequenced by PCR to confirm predicted DNA sequence of clones.

The resultant mutated Ras sequence was then prepared as an retroviral expression vector construct as described herein. One preferred expression construct for use in the present invention is the RCAS(A) construct. This expression vector is based on a series of replication competent avian sarcoma viruses with an enhanced Bryan polymerase (BP) for improved titre, and is specific for the A type envelope glycoprotein expressed on normal avian cells (Reviewed in Methods in Cell Biology, 52:179-214 (1997); see also, Hughes et al., J. Virol. 61:3004-3012 (1987); Fekete & Cepko, Mol. Cellular Biol. 13:2604-2613 (1993); Itoh et al., Development 122:291-300 (1996); and Stott et al., BioTechniques 24:660-666 (1998)). The complete sequence of RCAS(A), referred to herein as RCAS, is known to one of ordinary skill in the art and available on databases.

Five micrograms (ug) of RCAS constructs prepared were then transfected into the chicken immortalized fibroblast line, DF-1 (gift of Doug Foster, U. of Minn.). This cell line as well as primary chick embryo fibroblasts were capable of producing virus, however the DF-1 cell line produced higher titres. Viral supernatants were collected from subconfluent DF-1 producer cell lines in serum free CLM media [composition: F-10 media base supplemented with DMSO, folic acid, glutamic acid, and MEM vitamin solution]. Thirty-five ml of viral supernatant were concentrated by ultracentrifugation at 4°C for 2 hours at 22,000 rpm. These concentrated viral pellets were resuspended in 1/100 the original volume in serum-free CLM media, aliquoted and stored at -80°C. The titre was assessed by serial dilution of a control viral vector having a nucleotide sequence encoding green fluorescent protein (GFP), referred to as RCAS-GFP, infection on primary chick embryo fibroblasts that were incubated for 48-72 hours. The titres of viral stock that were obtained following concentration routinely exceeded 10^8 I.u./ml.

For the CAM assay using the viral stocks, cortisone acetate soaked Whatman filter disks 6 mm in diameter were prepared in 3 mg/ml cortisone acetate for 30 minutes in 95% ethanol. The disks were dried in a laminar flow hood and then soaked on 20 µl of viral stock per disk for 10 minutes. These disks were applied to the CAM of a 10 day chick embryos and sealed with cellophane tape and incubated at 37°C for 18-24 hr. Then either mock PBS or growth factors were added at a concentration of 5 µg/ml to the CAM in a 15 microliters (ul) volume of the appropriate virus stock as an additional boost of virus to the CAM tissue. After 72 hours, the CAMs were harvested and examined for changes in the angiogenic index as determined by double blind counting of the number of branch points in the CAM underlying the disk. For kinase assays, the tissue underlying the disk was harvested in RIPA, homogenized with a motorized grinder and Raf determined as previously described in Example 4. For immunofluorescence studies, CAM tissue underlying the disks were frozen in OCT, a cryopreservative, sectioned at 4 um, fixed in acetone for 1 minute, incubated in 3% normal goat serum for 1 hour, followed by an incubation in primary rabbit antibody as described previously (Eliceiri et al., J. Cell Biol., 140:1255-1263 (1998), washed in PBS and detected with a fluorescent secondary antibody.

The results, shown in FIG. 12, graphically reveal that infection with mutant null Ras, S17N, blocked growth factor-induced angiogenesis in the CAM, but had no effect on CAMs that were not exposed to bFGF to induce angiogenesis. Therefore, Ras is necessary for bFGF-induced angiogenesis.

C. Ras Signaling Through the Raf-MEK-ERK Pathway is a Crucial Regulator of Angiogenesis

To further assess the role of Ras in the Raf-MEK-ERK pathway in modulating angiogenesis, additional H-Ras mutant proteins were used in the CAM preparation as described above, the results of which are shown below and in FIG. 13. In this context, the present invention describes two categories of Ras function that can modulate angiogenesis. As previously discussed for Raf proteins, one category

contains Ras molecules that increase angiogenesis and, thus, are considered to be active proteins. Wild-type Ras along with various mutations are shown in the present invention to induce angiogenesis.

One preferred mutation of wild type H-Ras which functions in this context with respect to its ability to induce blood vessel growth and therefore increase tumor weight *in vivo* is the Ras G12V, also referred to as V12, mutant having a point mutation at amino acid (aa) residue position 12 changing glycine (G) to valine (V). This mutant Ras is constitutively active.

Another H-Ras mutant protein that is described for the present invention as a constitutive angiogenesis activator is Ras V12S35, where the glycine at position 12 was changed to valine (V) and the threonine (T) at position 35 was changed to a serine (S), both mutations resulting in Ras V12S35. This mutated H-Ras protein has been shown to only selectively activate the Raf-MEK-ERK pathway as shown in FIG. 13A.

A H-Ras negative regulator of angiogenesis is Ras V12C40 mutant, where the glycine at position 12 was changed to valine (V) as in Ras V12S35 but the other mutation was at position 40 where a tyrosine residue (Y) was changed to a cysteine (C), both mutations, thus, resulting in Ras V12C40. This mutant H-Ras is known to selectively activate the P1-3 kinase (P13K as shown in FIG. 13A) pathway that activates Akt and Rac. Thus, Ras V12C40 does not function in the Raf-MEK-ERK pathway and does not stimulate angiogenesis but rather would inhibit it. Proteins having mutation that confer inhibitory activity on angiogenesis are also referred to as dominant negative Ras proteins in that they inhibit neovascularization, including that resulting from endogenous activity of Ras as well as enhanced Ras activity resulting from growth factor stimulation. Thus, certain mutations of wild type H-Ras of the present invention can also function as a dominant negative with respect to their ability to block blood vessel growth, and for example, therefore decrease tumor weight *in vivo*. The three H-Ras constructs and mutant proteins have been previously described by Joneson et al., Science, 271:810-812 (1996).

With respect to the point mutations, any mutation resulting in the desired inhibitory or stimulatory activity is contemplated for use in this invention. Fusion protein constructs combining the desired Ras (or Raf proteins as shown in the Examples below) (mutation or fragment thereof) with expressed amino acid tags, antigenic epitopes, fluorescent protein, or other such protein or peptides are also contemplated, so long as the desired modulating effect of the Ras protein is intact.

To evaluate the roles of the additional Ras mutant proteins in signaling pathway activation of angiogenesis, the respective retroviral expression constructs were prepared as described above. Fifteen ul of high titer RCAS (A) virus encoding the Raf-MEK-ERK activating Ras construct, Ras V12S35, or the PI3 kinase activating Ras construct, Ras V12C40, were topically applied to filter disks in a 10-day old CAM preparation and results assessed as described above for the effect of the mutant Ras proteins on angiogenesis with respect to the selective activation of signaling pathways.

FIGs. 13A and 13B illustrate schematically and graphically respectively that infection with a mutant Ras construct, Ras V12S35, which selectively activates the Ras-Raf-MEK-ERK pathway, induced angiogenesis, whereas a mutant construct, Ras V12C40, which selectively activates the PI3K pathways did not. Thus, these results confirm that Ras V12S35 protein is a angiogenesis stimulator and that Ras-mediated activation of angiogenesis occurs through activation of the Raf-MEK-ERK pathway and not via the P13K pathway utilized by the H-Ras mutant V12C40.

D. <u>The MEK Component of the MEK-ERK Pathway is Required for Either Ras or Ras-Independent Raf Induced Angiogenesis</u>

To further assess the separate roles of Ras and Raf in the Raf-MEK-ERK pathway in modulating angiogenesis, a Raf mutant protein, referred to as Raf-Caax, that is targeted to the plasma membrane that is known to be constitutively and enzymatically active in the absence of Ras binding was used in the CAM preparations as described herein in conjunction with a known inhibitor of MEK activation, PD98059. FIG. 14 depicts the nucleotide sequence encoding the fusion protein

Raf-caax, where the nucleotide sequence encoding the carboxy terminus of human Raf (wt H-Raf) is fused with a nucleotide sequence of encoding a 20 amino acid residue sequence of the K-ras membrane localization domain (SEQ ID NO.: 6). FIG. 15 (SEQ ID NO.: 7) depicts the amino acid residue sequence of Raf-caax, the fusion protein generated from the fusion nucleotide sequence shown in FIG. 14. The fusion protein has been described by Leevers et al., Nature, 369:411-414 (1994) and Stokoe et al., Science, 264:1463-1467 (1994).

For assessing the Ras-independent Raf-induced angiogenesis along with angiogenesis induced by Raf, the MEK inhibitor, PD98059, was used in CAM preparations as described above. Virus encoding the activating Ras construct, Ras V12 (Ras G12V), prepared as described in Example 9C and the activating Raf construct, Raf-caax, were topically applied to filter disks as described in Example 9B. After 24 hours, one (1) nanomole of the MEK inhibitor, PD98059, was added to the disk. The CAMs were then evaluated as described in Example 9B and in FIG. 12. Data plotted is the mean ± SE of 20 embryos.

FIGs. 16A-16E and FIG. 16F, respectively, pictorially and graphically illustrate that the MEK inhibitor, PD98059, blocked angiogenesis (FIGs. 16C and 16E) induced by either mutant active Ras (FIG. 16B) or Raf (FIG. 16D). Thus, both Ras and Raf induce angiogenesis through the MEK-ERK pathway. The plotted data graphically depicts the results of the photographs of the individual treated CAMs.

10. Angiogenesis induced by Raf, but not Ras, is Refractory to Inhibition by Integrin Blockade

To determine how integrin signaling activates the Ras-Raf-MEK-ERK pathway resulting in angiogenesis, CAM assays with mutant active Ras and Raf constructs were performed in the presence of $\alpha_v\beta_3$ integrin-blocking antibodies. CAMs from 10-day old chick embryos were stimulated as described in FIGs. 9 and 12 with filter disks saturated with either PBS (control), bFGF, the RCAS(A) retroviral constructs G12V-Ras or Raf-caax. LM609, a monoclonal antibody to integrin $\alpha_v\beta_3$,

was intravenously delivered after 24 hours and angiogenesis was assessed by vessel branch point analysis after 72 hours. Representative CAMs are shown in the inset. Data is the mean ± SE of 20 embryos.

FIGs. 17A-17F and FIG. 17G, respectively, pictorially and graphically illustrate that angiogenesis induced by Raf, but not Ras, was refractory to inhibition by integrin blockade. Infection with both mutant active Ras and Raf constructs induced pronounced angiogenesis as shown respectively in FIGs. 17B and 17C, but only Ras-induced angiogenesis was inhibited by $\alpha_v\beta_3$ integrin-blocking antibodies as shown in FIG. 17E. Since the Raf construct used in the assay is Ras-independent, the lack of integrin inhibition of Raf-induced angiogenesis indicates that integrin signaling occurs at or before Ras-mediated activation of Raf. The plotted data graphically depicts the results of the photographs of the individual treated CAMs.

11. Regulation of the Ras-Raf-MEK-ERK Pathway by Focal Adhesion Kinase

To determine the role of growth factor receptor activation of the Ras-Raf-MEK-ERK angiogenesis pathway, CAM angiogenesis assays were performed as described above with either Ras V12 or Raf-caax expressed proteins in the presence of a mutant null focal adhesion kinase, referred to as FRNK, which is an inactive focal adhesion kinase.

RCAS(A) viruses encoding Ras V12 or Raf-caax, prepared as described above, were topically applied as described in Example 9B (FIG. 12) along with RCAS(B) virus encoding FAK-related-null-kinase (FRNK) to the CAM filter disk. Data is the mean ± SE of 20 embryos.

The results are shown in FIGs. 18A-18D and 18E. FIGs. 18A-18D pictorially illustrate that co-infection of CAMs with a mutant null focal adhesion kinase, FRNK, blocked Ras, but not Raf-induced angiogenesis, as indicated by a paucity of blood vessels in FIG. 18B as compared to untreated Ras (FIG. 18A), untreated Raf (FIG. 18C) and FRNK-treated Raf (FIG. 18 D). The plotted data graphically depicts the results of the photographs of the individual treated CAMs.

The data in the CAM assay was confirmed in the murine subcutaneous angiogenesis model, prepared as previously described. Angiogenesis was induced by injecting 250 ul of ice-cold, growth factor-reduced matrigel containing either 400 ng/ml bFGF or Moloney retrovirus expressing packaging cells expressing the described gene, subcutaneously in the mouse flank. FRNK retrovirus was added to matrigel as high titer virus packaged with the vsv.g coat protein. Five days later, endothelial-specific FITC-conjugated Bandeiriea Simplifica B5 lectin was injected via the tail vein and allowed to circulate. Angiogenesis was then quantitated by removing, extracting, and assaying the angiogenic tissue for fluorescent content.

FIGs. 19A and 19B-19G, respectively, graphically and pictorially, illustrate that FRNK blocked bFGF and Ras-, but not Raf, -induced angiogenesis in a murine subcutaneous angiogenesis model.

To verify the level at which kinase activation occurs in the Ras-Raf-MEK-ERK pathway, CAMS were co-infected with a retrovirus expressing FRNK, the mutant null focal adhesion kinase, with either Ras G12V or Raf-caax. CAMs were treated as described in FIG. 18 with the exception that after 24 hours the angiogenic tissue was resected, solubilized, Raf immunoprecipitated, and Raf activity assessed by its capacity to phosphorylate kinase-dead MEK. FIGs. 20A and 20B illustrate that co-infection of CAMs with a mutant null focal adhesion kinase, FRNK, blocked Ras-induced activation of Raf. FIG. 20A shows the immunoprecipated active versus total Raf proteins assayed under each of the combinations above the results. FIG. 20B graphically plots the results of the active Raf determinations under those conditions. Thus, FRNK does not directly inhibit the activity of Raf but rather inhibits the activation of Raf by Ras.

12. Discussion

The above studies indicates that Raf kinase is necessary and sufficient for angiogenesis *in vivo*. Further, targeting of mutationally inactive Raf kinase to growing blood vessels induces local endothelial apoptosis. The same targeting also suppresses

angiogenesis which results in suppression and even regression of pre-existing human tumors.

The retroviral delivery of a gene encoding mutationally inactive forms of Raf kinase (Raf K375M) demonstrated a substantial impact on tumor angiogenesis *in vivo*. Importantly, the retroviral vector used specifically infects proliferating cells of murine lineage. Therefore, only the vascular compartment of human tumor xenografts was infected (FIGs. 1 and 4). Delivery of inactive Raf K375M kinase was found to suppress growth factor-induced Raf kinase activity *in vitro* and block growth factor-induced angiogenesis *in vivo* (FIGs. 2 & 3). In contrast, retroviral delivery of a mutationally active form of Raf kinase (Raf 306-648) was sufficient to induce angiogenesis *in vivo* (FIG. 4). Furthermore, the delivery of virus expressing inactive Raf kinase to the tumor in mice was found to induce apoptosis in a endothelial-specific manner (FIG. 5). Finally, animals inoculated with human tumors and then treated with the virus expressing inactive Raf experienced a rapid tumor regression which was maintained throughout the time-course of the experiment (FIG. 6). Therefore, Raf kinase is both sufficient and necessary for angiogenesis and targeting this kinase can suppress angiogenesis and obviate angiogenesis-dependent disease.

As a result of the foregoing angiogenesis assays in mouse and chicken as described in Examples 9-11, depicted in FIGs. 9, 12, 13, and 16-20, the present invention provides angiogenesis activator proteins in Raf-caax, Ras G12V Ras, and Ras V12S35 and angiogenesis inhibitor proteins in Ras S17N and Ras V12C40. Furthermore, the studies provide the basis for understanding the Ras-mediated activation of Raf in the Ras-Raf-MEK-ERK pathway identifying that Ras is necessary for activation of Raf but integrin-mediated signaling interacts at of before Raf activation but not downstream thereof.

While the foregoing written specification is sufficient to enable one skilled in the art to practice the invention, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

What Is Claimed Is:

1. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treating disease conditions by modulating angiogenesis, and wherein said pharmaceutical composition comprises a Raf protein or an oligonucleotide having a nucleotide sequence capable of expressing said protein.

2. The article of manufacture of claim 1 wherein said Raf protein is an active Raf protein and said modulating potentiates angiogenesis.

3. The article of manufacture of claim 2 wherein said active Raf protein is wild-type Raf.

4. The article of manufacture of claim 3 wherein said active Raf protein is a fusion protein.

5. The article of manufacture of claim 4 wherein said active Raf fusion protein is Raf-caax.

6. The article of manufacture of claim 2 wherein said tissue has poor circulation.

7. The article of manufacture of claim 1 wherein said Raf protein is an inactive Raf protein and said modulating inhibits angiogenesis.

8. The article of manufacture of claim 7 wherein said inactive Raf protein has a mutation at residue 375 such that the amino acid at position 375 is not lysine.

9. The article of manufacture of claim 7 wherein said tissue is inflamed and said condition is arthritis or rheumatoid arthritis.

10. The article of manufacture of claim 7 wherein said tissue is a solid tumor or solid tumor metastasis.

11. The article of manufacture of claim 10 wherein said administering is conducted in conjunction with chemotherapy.

12. The article of manufacture of claim 7 wherein said tissue is retinal tissue and said condition is retinopathy, diabetic retinopathy or macular degeneration.

13. The article of manufacture of claim 7 wherein said tissue is at the site of coronary angioplasty and said condition is restenosis.

14. The article of manufacture of claim 1 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

15. The article of manufacture of claim 1 wherein said administering comprises a single dose intravenously.

16. The article of manufacture of claim 1 wherein said pharmaceutical composition further comprises a liposome.

17. The article of manufacture of claim 1 wherein said pharmaceutical composition comprises a viral expression vector capable of expressing said nucleotide sequence.

18. The article of manufacture of claim 1 wherein said pharmaceutical composition comprises an non-viral expression vector capable of expressing said nucleotide sequence.

19. A method for modulating angiogenesis in a tissue associated with a disease condition comprising administering to said tissue an angiogenesis modulating amount of a pharmaceutical composition comprising a Raf protein or a nucleotide sequence capable of expressing said protein.

20. The method of claim 19 wherein said Raf protein is an active Raf protein and said modulating potentiates angiogenesis.

21. The method of claim 20 wherein said active Raf protein is wild-type Raf.

22. The method of claim 21 wherein said active Raf protein is a fusion protein.

23. The method of claim 22 wherein said active Raf fusion protein is Raf-caax.

24. The method of claim 20 wherein said tissue has abnormal circulation.

25. The method of claim 19 wherein said Raf protein is an inactive Raf protein and said modulating inhibits angiogenesis.

26. The method of claim 25 wherein said inactive Raf protein has a mutation at residue 375 such that the amino acid at position 375 is not lysine.

27. The method of claim 25 wherein said tissue is inflamed and said condition is arthritis or rheumatoid arthritis.

28. The method of claim 25 wherein said tissue is a solid tumor or solid tumor metastasis.

29. The method of claim 28 wherein said administering is conducted in conjunction with chemotherapy.

30. The method of claim 25 wherein said tissue is retinal tissue and said condition is retinopathy, diabetic retinopathy or macular degeneration.

31. The method of claim 25 wherein said tissue is at the site of coronary angioplasty and said tissue is at risk for restenosis.

32. The method of claim 19 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

33. The method of claim 19 wherein said administering comprises a single dose intravenously.

34. The method of claim 19 wherein said pharmaceutical composition further comprises a liposome.

35. The method of claim 19 wherein said pharmaceutical composition comprises an retroviral expression vector capable of expressing said nucleotide sequence.

36. The method of claim 19 wherein said pharmaceutical composition comprises an non-viral expression vector capable of expressing said nucleotide sequence.

37. A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid,

said nucleic acid having a nucleic acid segment encoding for a Raf protein, said Raf protein having kinase activity, and a pharmaceutically acceptable carrier or excipient.

38. A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid, said nucleic acid having a nucleic acid segment encoding for a Raf protein, said Raf protein having kinase activity, and a pharmaceutically acceptable carrier or excipient.

39. A pharmaceutical composition for inhibiting angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid, said nucleic acid having a nucleic acid segment encoding for a Raf protein, said Raf protein having no kinase activity, and a pharmaceutically acceptable carrier or excipient.

40. A pharmaceutical composition for inhibiting angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid, said nucleic acid having a nucleic acid segment encoding for a Raf protein, said Raf protein having no kinase activity, and a pharmaceutically acceptable carrier or excipient.

41. A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a therapeutic amount of a Raf protein, said Raf protein having kinase activity, and a pharmaceutically acceptable carrier or excipient.

42. A pharmaceutical composition for inhibiting angiogenesis in a target mammalian tissue comprising a therapeutic amount of a Raf protein, said Raf protein having no kinase activity, and a pharmaceutically acceptable carrier or excipient.

43. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treating disease conditions by modulating angiogenesis, and wherein said pharmaceutical composition

comprises a Ras protein or an oligonucleotide having a nucleotide sequence capable of expressing said protein.

44. An article of manufacture according to claim 43 wherein said Ras protein or oligonucleotide encoding said protein is an inhibitory Ras protein.

45. An article of manufacture of claim 44, wherein said inhibitory Ras is Ras V12C40.

46. An article of manufacture of claim 44, wherein said inhibitory Ras is Ras S17N.

47. An article of manufacture according to claim 43 wherein said Ras protein or oligonucleotide encoding said protein is a stimulatory Ras protein.

48. An article of manufacture of claim 47, wherein said stimulatory Ras is Ras G12V.

49. An article of manufacture of claim 47, wherein said stimulatory Ras is Ras V12S35.

50. A method for modulating angiogenesis in a tissue associated with a disease condition comprising administering to said tissue an angiogenesis modulating amount of a pharmaceutical composition comprising a Ras protein or a nucleotide sequence encoding for said protein.

51. The method according to claim 50 wherein said Ras protein or oligonucleotide encoding for said protein is an inactive Ras protein.

52. The method of claim 51, wherein said inactive Ras is Ras V12C40.

53. The method of claim 51, wherein said inactive Ras is Ras S17N.

54. The method according to claim 50 wherein said Ras protein or oligonucleotide encoding for said protein is an active Ras protein.

55. The method of claim 54, wherein said active Ras is Ras GV12.

56. The method of claim 54, wherein said active Ras is Ras V12S35.

57. A pharmaceutical composition for modulating angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid, said nucleic acid having a nucleic acid segment encoding for a Ras protein, said Ras

protein having angiogenesis modulating activity, in a pharmaceutically acceptable carrier or excipient.

58. A pharmaceutical composition of claim 57, for inhibiting angiogenesis in a target mammalian tissue wherein said Ras protein has angiogenesis inhibitor activity.

59. A pharmaceutical composition of claim 58, wherein said Ras protein is Ras V12C40.

60. A pharmaceutical composition of claim 58, wherein said Ras protein is Ras S17N.

61. A pharmaceutical composition of claim 57, wherein said Ras protein has angiogenesis activating activity.

62. A pharmaceutical composition of claim 61, wherein said Ras protein is Ras G12V.

63. A pharmaceutical composition of claim 61, wherein said Ras protein is Ras V12S35.

64. A pharmaceutical composition for modulating angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid, said nucleic acid having a nucleic acid segment encoding for a Ras protein, and said Ras protein having angiogenesis modulating activity, and a pharmaceutically acceptable carrier or excipient.

65. A method for modulating angiogenesis in a tissue associated with a disease condition comprising administering to said tissue an angiogenesis modulating amount of a pharmaceutical composition comprising a Raf protein or a nucleotide sequence capable of expressing said protein, and a Ras protein or a nucleotide sequence capable of expressing said protein.

66. A method of claim 65 wherein said modulation is an inhibition of angiogenesis, and at least one of said Raf and Ras proteins are inactive.

67. A method of claim 65 wherein said modulation is an stimulation of angiogenesis, and at least one of said Raf and Ras proteins are active.

ABSTRACT

The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Raf and/or Ras protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Raf or Ras protein, or modified forms thereof.



FIGURE 1



FIGURE 2


A
B
angiogenic index
(X-control)
6
5
4
3
2
1
0
*
**
Control
bFGF
bFGF +
ATPγ-RAF

FIGURE 3



FIGURE 4


vWF
Endothelial cells
Flag tag
infected cells
apoptag
apoptotic cells
merge
infected, apoptotic ECs

FIGURE 5



FIGURE 6

HUMAN c-RAF cDNA

ccgaatgtgaccgcctcccgctccctcacccgccgcggggaggaggagcgggcgagaagctgccgccgaacgacaggacg
ttggggcggcctggctccctcaggtttaagaattgtttaagctgcatcaatggagcacatacagggagcttggaagacga
tcagcaatggttttggattcaaagatgccgtgtttgatggctccagctgcatctctcctacaatagttcagcagtttggc
tatcagcgccgggcatcagatgatggcaaactcacagatccttctaagacaagcaacactatccgtgttttcttgccgaa
caagcaaagaacagtggtcaatgtgcgaaatggaatgagcttgcatgactgccttatgaaagcactcaaggtgaggggcc
tgcaaccagagtgctgtgcagtgttcagacttctccacgaacacaaaggtaaaaaagcacgcttagattggaatactgat
gctgcgtctttgattggagaagaacttcaagtagatttcctggatcatgttcccctcacaacacacaactttgctcggaa
gacgttcctgaagcttgccttctgtgacatctgtcagaaattcctgctcaatggatttcgatgtcagacttgtggctaca
aatttcatgagcactgtagcaccaaagtacctactatgtgtgtggactggagtaacatcagacaactcttattgtttcca
aattccactattggtgatagtggagtcccagcactaccttctttgactatgcgtcgtatgcgagagtctgtttccaggat
gcctgttagttctcagcacagatattctacacctcacgccttcacctttaacacctccagtccctcatctgaaggttccc
tctcccagaggcagaggtcgacatccacacctaatgtccacatggtcagcaccacgctgcctgtggacagcaggatgatt
gaggatgcaattcgaagtcacagcgaatcagcctcaccttcagccctgtccagtagccccaacaatctgagcccaacagg
ctggtcacagccgaaaaccccccgtgccagcacaaagagagcgggcaccagtatctgggacccaggagaaaaacaaaatta
ggcctcgtggacagagagattcaagctattattgggaaatagaagccagtgaagtgatgctgtccactcggattgggtca
ggctcttttggaactgtttataagggtaaatggcacggagatgttgcagtaaagatcctaaaggttgtcgacccaacccc
agagcaattccaggccttcaggaatgaggtggctgttctgcgcaaaacacggcatgtgaacattctgcttttcatggggt
acatgacaaaggacaacctggcaattgtgacccagtggtgcgagggcagcagcctctacaaacacctgcatgtccaggag
accaagtttcagatgttccagctaattgacattgcccggcagacggctcagggaatggactatttgcatgcaaagaacat
catccatagagacatgaaatccaacaatatatttctccatgaaggcttaacagtgaaaattggagattttggtttggcaa
cagtaaagtcacgctggagtggttctcagcaggttgaacaacctactggctctgtcctctggatggccccagaggtgatc
cgaatgcaggataacaacccattcagtttccagtcggatgtctactcctatggcatcgtattgtatgaactgatgacggg
ggagcttccttattctcacatcaacaaccgagatcagatcatcttcatggtgggccgaggatatgcctccccagatctta
gtaagctatataagaactgccccaaagcaatgaagaggctggtagctgactgtgtgaagaaagtaaaggaagagaggcct
ctttttccccagatcctgtcttccattgagctgctccaacactctctaccgaagatcaaccggagcgcttccgagccatc
cttgcatcgggcagcccacactgaggatatcaatgcttgcacgctgaccacgtccccgaggctgcctgtcttctagttga
ctttgcacctgtcttcaggctgccaggggaggaggagaagccagcaggcaccacttttctgctccctttctccagaggca
gaacacatgttttcagagaagctctgctaaggaccttctagactgctcacagggccttaacttcatgttgccttctttc
tatccctttgggccctgggagaaggaagccatttgcagtgctggtgtgtcctgctccctccccacattccccatgctcaa
ggcccagccttctgtagatgcgcaagtggatgttgatggtagtacaaaaagcaggggcccagccccagctgttggctaca
tgagtatttagaggaagtaaggtagcaggcagtccagccctgatgtggagacacatgggattttggaaatcagcttctgg
aggaatgcatgtcacaggcgggactttcttcagagagtggtgcagcgccagacattttgcacataaggcaccaaacagcc
caggactgccgagactctggccgcccgaaggagcctgctttggtactatggaacttttcttaggggacacgtcctccttt
cacagcttctaaggtgtccagtgcattgggatggttttccaggcaaggcactcggccaatccgcatctcagccctctcag
gagcagtcttccatcatgctgaattttgtcttccaggagctgcccctatggggcgggccgcagggccagcctgtttctct
aacaaacaaacaaacaaacagccttgtttctctagtcacatcatgtgtatacaaggaagccaggaatacaggttttcttg
atgatttgggttttaattttgttttttattgcacctgacaaaatacagttatctgatggtccctcaattatgttatttttaa
taaaataaattaaattt

FIGURE 7

HUMAN c-RAF ENCODED PROTEIN

MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTD
PSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAV
FRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFL
KLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFP
NSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPS
SEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSS
PNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIE
ASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNE
VAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKF
QMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGL
ATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIV
LYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVA
DCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINAC
TLTTSPRLPVF

FIGURE 8



FIGURE 9

atgacggaatataagctggtggtggtgggcgccggcggtgtgggcaagagtgcgctgaccatccagctgatccagaacca

ttttgtggacgaatacgaccccactatagaggattcctaccggaagcaggtggtcattgatggggagacgtgcctgttgg

acatcctggataccgccggccaggaggagtacagcgccatgcgggaccagtacatgcgcaccggggagggcttcctgtgt

gtgtttgccatcaacaacaccaagtcttttgaggacatccaccagtacagggagcagatcaaacgggtgaaggactcgga

tgacgtgcccatggtgctggtggggaacaagtgtgacctggctgcacgcactgtggaatctcggcaggctcaggacctcg

cccgaagctacggcatcccctacatcgagacctcggccaagacccggcagggagtggaggatgccttctacacgttggtg

cgtgagatccggcagcacaagctgcggaagctgaaccctcctgatgagagtggccccggctgcatgagctgcaagtgtgt

gctctcctga

FIGURE 10

M T E Y K L V V V G A G G V G K S A L T I Q L I Q N H F V D E Y D P T I E D S Y

R K Q V V I D G E T C L L D I L D T A G Q E E Y S A M R D Q Y M R T G E G F L C

V F A I N N T K S F E D I H Q Y R E Q I K R V K D S D D V P M V L V G N K C D L

A A R T V E S R Q A Q D L A R S Y G I P Y I E T S A K T R Q G V E D A F Y T L V

R E I R Q H K L R K L N P P D E S G P G C M S C K C V L S

FIGURE 11



FIGURE 12



FIGURE 13A



FIGURE 13B

atggagcacatacagggagcttggaagacgatcagcaatggttttggattcaaagatgccgtgtttgatggctccagctg
catctctcctacaatagttcagcagtttggctatcagcgccgggcatcagatgatggcaaactcacagatccttctaaga
caagcaacactatccgtgttttcttgccgaacaagcaaagaacagtggtcaatgtgcgaaatggaatgagcttgcatgac
tgccttatgaaagcactcaaggtgaggggcctgcaaccagagtgctgtgcagtgttcagacttctccacgaacacaaagg
taaaaaagcacgcttagattggaatactgatgctgcgtctttgattggagaagaacttcaagtagatttcctggatcatg
ttcccctcacaacacacaactttgctcggaagacgttcctgaagcttgccttctgtgacatctgtcagaaattcctgctc
aatggatttcgatgtcagacttgtggctacaaatttcatgagcactgtagcaccaaagtacctactatgtgtgtggactg
gagtaacatcagacaactcttattgtttccaaattccactattggtgatagtggagtcccagcactaccttctttgacta
tgcgtcgtatgcgagagtctgtttccaggatgcctgttagttctcagcacagatattctacacctcacgccttcaccttt
aacacctccagtccctcatctgaaggttccctctcccagaggcagaggtcgacatccacacctaatgtccacatggtcag
caccacgctgcctgtggacagcaggatgattgaggatgcaattcgaagtcacagcgaatcagcctcaccttcagccctgt
ccagtagccccaacaatctgagcccaacaggctggtcacagccgaaaacccccgtgccagcacaaagagagcgggcacca
gtatctgggacccaggagaaaaacaaaattaggcctcgtggacagagagattcaagctattattgggaaatagaagccag
tgaagtgatgctgtccactcggattgggtcaggctcttttggaactgtttataagggtaaatggcacggagatgttgcag
taaagatcctaaaggttgtcgacccaaccccagagcaattccaggccttcaggaatgaggtggctgttctgcgcaaaaca
cggcatgtgaacattctgcttttcatggggtacatgacaaaggacaacctggcaattgtgacccagtggtgcgagggcag
cagcctctacaaacacctgcatgtccaggagaccaagtttcagatgttccagctaattgacattgcccggcagacggctc
agggaatggactatttgcatgcaaagaacatcatccatagagacatgaaatccaacaatatatttctccatgaaggctta
acagtgaaaattggagattttggtttggcaacagtaaagtcacgctggagtggttctcagcaggttgaacaacctactgg
ctctgtcctctggatggccccagaggtgatccgaatgcaggataacaacccattcagtttccagtcggatgtctactcct
atggcatcgtattgtatgaactgatgacgggggagcttccttattctcacatcaacaaccgagatcagatcatcttcatg
gtgggccgaggatatgcctccccagatcttagtaagctatataagaactgccccaaagcaatgaagaggctggtagctga
ctgtgtgaagaaagtaaaggaagagaggcctctttttccccagatcctgtcttccattgagctgctccaacactctctac
cgaagatcaaccggagcgcttccgagccatccttgcatcgggcagcccacactgaggatatcaatgcttgcacgctgacc
acgtccccgaggctgcctgtcttc tactcgttcctgccgttcttcttcttcttctcgttctgtttcacgcctagtacattc

FIGURE 14

MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQR
RASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHD
CLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAAS
LIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLL
NGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNST
IGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTF
NTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDA
IRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAP
VSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSF
GTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKT
RHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKF
QMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGL
TVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQ
DNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFM
VGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFP
QILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLT
TSPRLPVFYSFLPFFFFFSFCFTPSTF

FIGURE 15


A
Control
B
G12V-Ras
C
G12V-Ras + PD98059


D
Raf-caax
Raf-caax + PD98059
E


F
Blood Vessel Branch Points
300
200
100
0
*
*
**
**
G12V-Ras - + + - -
Raf-caax - - - + +
PD9805 - - + - +

FIGURE 16


A
B
C
bFGF
G12V-Ras
Raf-caax
D
E
F
bFGF +
anti-$\alpha_v\beta_3$
G12V-Ras +
anti-$\alpha_v\beta_3$
Raf-caax +
anti-$\alpha_v\beta_3$
G
Blood Vessel
Branch Points
240
160
80
0
control
bFGF
G12V-Ras
Raf-caax
bFGF
G12V-Ras
Raf-caax
+ anti-$\alpha_v\beta_3$

FIGURE 17


A
B
G12V-Ras
G12V-Ras + FRNK
C
D
Raf-caax
Raf-caax + FRNK
E
Blood Vessel Branch Points
320
240
160
80
0
*
**
control
bFGF
G12V Ras
Raf-caax
bFGF
G12V Ras
Raf-caax
+ FRNK

FIGURE 18


A
10
5
0
angiogenic index (X-control)
Control
bFGF
G12V-Ras
Raf-caax
bFGF
G12V-Ras
Raf-caax
+ FRNK
B
bFGF
C
G12V-Ras
D
Raf-caax
+ empty vector
E
F
G
+ FRNK

FIGURE 19



FIGURE 20A



FIGURE 20B

SEQUENCE LISTING

<110> HOOD, John
ELICEIRI, Brian
CHERESH, David

<120> Methods and Compositions Useful for Modulation of Angiogenesis Using Tyrosine Kinase Raf and Ras

<130> TSRI 710.2

<140>
<141>

<150> US 60/148,924
<151> 1999-08-13

<150> US 60/215,951
<151> 2000-07-05

<160> 7

<170> PatentIn Ver. 2.0

<210> 1
<211> 2977
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (130)..(2073)

<400> 1
ccgaatgtga ccgcctcccg ctcccctcacc cgccgcgggg aggaggagcg ggcgagaagc 60

tgccgccgaa cgacaggacg ttggggcggc ctggctccct caggtttaag aattgtttaa 120

gctgcatca atg gag cac ata cag gga gct tgg aag acg atc agc aat ggt 171
Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly
1 5 10

ttt gga ttc aaa gat gcc gtg ttt gat ggc tcc agc tgc atc tct cct 219
Phe Gly Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro
15 20 25 30

aca ata gtt cag cag ttt ggc tat cag cgc cgg gca tca gat gat ggc 267
Thr Ile Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly
35 40 45

aaa ctc aca gat cct tct aag aca agc aac act atc cgt gtt ttc ttg 315

```
Lys Leu Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu
            50                  55                  60

ccg aac aag caa aga aca gtg gtc aat gtg cga aat gga atg agc ttg   363
Pro Asn Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu
        65                  70                  75

cat gac tgc ctt atg aaa gca ctc aag gtg agg ggc ctg caa cca gag   411
His Asp Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu
    80                  85                  90

tgc tgt gca gtg ttc aga ctt ctc cac gaa cac aaa ggt aaa aaa gca   459
Cys Cys Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala
 95                 100                 105                 110

cgc tta gat tgg aat act gat gct gcg tct ttg att gga gaa gaa ctt   507
Arg Leu Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu
                115                 120                 125

caa gta gat ttc ctg gat cat gtt ccc ctc aca aca cac aac ttt gct   555
Gln Val Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala
            130                 135                 140

cgg aag acg ttc ctg aag ctt gcc ttc tgt gac atc tgt cag aaa ttc   603
Arg Lys Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe
        145                 150                 155

ctg ctc aat gga ttt cga tgt cag act tgt ggc tac aaa ttt cat gag   651
Leu Leu Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu
    160                 165                 170

cac tgt agc acc aaa gta cct act atg tgt gtg gac tgg agt aac atc   699
His Cys Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile
175                 180                 185                 190

aga caa ctc tta ttg ttt cca aat tcc act att ggt gat agt gga gtc   747
Arg Gln Leu Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val
                195                 200                 205

cca gca cta cct tct ttg act atg cgt cgt atg cga gag tct gtt tcc   795
Pro Ala Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser
            210                 215                 220

agg atg cct gtt agt tct cag cac aga tat tct aca cct cac gcc ttc   843
Arg Met Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe
        225                 230                 235

acc ttt aac acc tcc agt ccc tca tct gaa ggt tcc ctc tcc cag agg   891
Thr Phe Asn Thr Ser Ser Pro Ser Ser Glu Gly Ser Leu Ser Gln Arg
    240                 245                 250
```

```
cag agg tcg aca tcc aca cct aat gtc cac atg gtc agc acc acg ctg     939
Gln Arg Ser Thr Ser Thr Pro Asn Val His Met Val Ser Thr Thr Leu
255                 260                 265                 270

cct gtg gac agc agg atg att gag gat gca att cga agt cac agc gaa     987
Pro Val Asp Ser Arg Met Ile Glu Asp Ala Ile Arg Ser His Ser Glu
                275                 280                 285

tca gcc tca cct tca gcc ctg tcc agt agc ccc aac aat ctg agc cca     1035
Ser Ala Ser Pro Ser Ala Leu Ser Ser Ser Pro Asn Asn Leu Ser Pro
            290                 295                 300

aca ggc tgg tca cag ccg aaa acc ccc gtg cca gca caa aga gag cgg     1083
Thr Gly Trp Ser Gln Pro Lys Thr Pro Val Pro Ala Gln Arg Glu Arg
        305                 310                 315

gca cca gta tct ggg acc cag gag aaa aac aaa att agg cct cgt gga     1131
Ala Pro Val Ser Gly Thr Gln Glu Lys Asn Lys Ile Arg Pro Arg Gly
    320                 325                 330

cag aga gat tca agc tat tat tgg gaa ata gaa gcc agt gaa gtg atg     1179
Gln Arg Asp Ser Ser Tyr Tyr Trp Glu Ile Glu Ala Ser Glu Val Met
335                 340                 345                 350

ctg tcc act cgg att ggg tca ggc tct ttt gga act gtt tat aag ggt     1227
Leu Ser Thr Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly
                355                 360                 365

aaa tgg cac gga gat gtt gca gta aag atc cta aag gtt gtc gac cca     1275
Lys Trp His Gly Asp Val Ala Val Lys Ile Leu Lys Val Val Asp Pro
            370                 375                 380

acc cca gag caa ttc cag gcc ttc agg aat gag gtg gct gtt ctg cgc     1323
Thr Pro Glu Gln Phe Gln Ala Phe Arg Asn Glu Val Ala Val Leu Arg
        385                 390                 395

aaa aca cgg cat gtg aac att ctg ctt ttc atg ggg tac atg aca aag     1371
Lys Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Met Thr Lys
    400                 405                 410

gac aac ctg gca att gtg acc cag tgg tgc gag ggc agc agc ctc tac     1419
Asp Asn Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr
415                 420                 425                 430

aaa cac ctg cat gtc cag gag acc aag ttt cag atg ttc cag cta att     1467
Lys His Leu His Val Gln Glu Thr Lys Phe Gln Met Phe Gln Leu Ile
                435                 440                 445

gac att gcc cgg cag acg gct cag gga atg gac tat ttg cat gca aag     1515
Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys
            450                 455                 460
```

aac atc atc cat aga gac atg aaa tcc aac aat ata ttt ctc cat gaa 1563
Asn Ile Ile His Arg Asp Met Lys Ser Asn Asn Ile Phe Leu His Glu
465 470 475

ggc tta aca gtg aaa att gga gat ttt ggt ttg gca aca gta aag tca 1611
Gly Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser
480 485 490

cgc tgg agt ggt tct cag cag gtt gaa caa cct act ggc tct gtc ctc 1659
Arg Trp Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu
495 500 505 510

tgg atg gcc cca gag gtg atc cga atg cag gat aac aac cca ttc agt 1707
Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser
515 520 525

ttc cag tcg gat gtc tac tcc tat ggc atc gta ttg tat gaa ctg atg 1755
Phe Gln Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met
530 535 540

acg ggg gag ctt cct tat tct cac atc aac aac cga gat cag atc atc 1803
Thr Gly Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile
545 550 555

ttc atg gtg ggc cga gga tat gcc tcc cca gat ctt agt aag cta tat 1851
Phe Met Val Gly Arg Gly Tyr Ala Ser Pro Asp Leu Ser Lys Leu Tyr
560 565 570

aag aac tgc ccc aaa gca atg aag agg ctg gta gct gac tgt gtg aag 1899
Lys Asn Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys
575 580 585 590

aaa gta aag gaa gag agg cct ctt ttt ccc cag atc ctg tct tcc att 1947
Lys Val Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile
595 600 605

gag ctg ctc caa cac tct cta ccg aag atc aac cgg agc gct tcc gag 1995
Glu Leu Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu
610 615 620

cca tcc ttg cat cgg gca gcc cac act gag gat atc aat gct tgc acg 2043
Pro Ser Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr
625 630 635

ctg acc acg tcc ccg agg ctg cct gtc ttc tagttgactt tgcacctgtc 2093
Leu Thr Thr Ser Pro Arg Leu Pro Val Phe
640 645

ttcaggctgc caggggagga ggagaagcca gcaggcacca cttttctgct ccctttctcc 2153

agaggcagaa cacatgtttt cagagaagct ctgctaagga ccttctagac tgctcacagg 2213

gccttaactt catgttgcct tcttttctat ccctttgggc cctgggagaa ggaagccatt 2273

tgcagtgctg gtgtgtcctg ctccctcccc acattcccca tgctcaaggc ccagccttct 2333

gtagatgcgc aagtggatgt tgatggtagt acaaaaagca ggggcccagc cccagctgtt 2393

ggctacatga gtatttagag gaagtaaggt agcaggcagt ccagccctga tgtggagaca 2453

catgggattt tggaaatcag cttctggagg aatgcatgtc acaggcggga ctttcttcag 2513

agagtggtgc agcgccagac attttgcaca taaggcacca aacagcccag gactgccgag 2573

actctggccg cccgaaggag cctgctttgg tactatggaa cttttcttag gggacacgtc 2633

ctcctttcac agcttctaag gtgtccagtg cattgggatg gttttccagg caaggcactc 2693

ggccaatccg catctcagcc ctctcaggag cagtcttcca tcatgctgaa ttttgtcttc 2753

caggagctgc ccctatgggg cgggccgcag ggccagcctg tttctctaac aaacaaacaa 2813

acaaacagcc ttgtttctct agtcacatca tgtgtataca aggaagccag gaatacaggt 2873

tttcttgatg atttgggttt taatttttgtt tttattgcac ctgacaaaat acagttatct 2933

gatggtccct caattatgtt attttaataa aataaattaa attt 2977

<210> 2
<211> 648
<212> PRT
<213> Homo sapiens

<400> 2

```
Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly Phe Gly
  1               5                  10                  15

Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro Thr Ile
             20                  25                  30

Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly Lys Leu
         35                  40                  45

Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu Pro Asn
     50                  55                  60

Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu His Asp
 65                  70                  75                  80

Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu Cys Cys
```

85 90 95

Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala Arg Leu
100 105 110

Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu Gln Val
115 120 125

Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala Arg Lys
130 135 140

Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe Leu Leu
145 150 155 160

Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu His Cys
165 170 175

Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile Arg Gln
180 185 190

Leu Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val Pro Ala
195 200 205

Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser Arg Met
210 215 220

Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe Thr Phe
225 230 235 240

Asn Thr Ser Ser Pro Ser Ser Glu Gly Ser Leu Ser Gln Arg Gln Arg
245 250 255

Ser Thr Ser Thr Pro Asn Val His Met Val Ser Thr Thr Leu Pro Val
260 265 270

Asp Ser Arg Met Ile Glu Asp Ala Ile Arg Ser His Ser Glu Ser Ala
275 280 285

Ser Pro Ser Ala Leu Ser Ser Ser Pro Asn Asn Leu Ser Pro Thr Gly
290 295 300

Trp Ser Gln Pro Lys Thr Pro Val Pro Ala Gln Arg Glu Arg Ala Pro
305 310 315 320

Val Ser Gly Thr Gln Glu Lys Asn Lys Ile Arg Pro Arg Gly Gln Arg
325 330 335

Asp Ser Ser Tyr Tyr Trp Glu Ile Glu Ala Ser Glu Val Met Leu Ser
340 345 350

Thr Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp

355 360 365

His Gly Asp Val Ala Val Lys Ile Leu Lys Val Val Asp Pro Thr Pro
370 375 380

Glu Gln Phe Gln Ala Phe Arg Asn Glu Val Ala Val Leu Arg Lys Thr
385 390 395 400

Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Met Thr Lys Asp Asn
405 410 415

Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr Lys His
420 425 430

Leu His Val Gln Glu Thr Lys Phe Gln Met Phe Gln Leu Ile Asp Ile
435 440 445

Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Asn Ile
450 455 460

Ile His Arg Asp Met Lys Ser Asn Asn Ile Phe Leu His Glu Gly Leu
465 470 475 480

Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp
485 490 495

Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu Trp Met
500 505 510

Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser Phe Gln
515 520 525

Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met Thr Gly
530 535 540

Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile Phe Met
545 550 555 560

Val Gly Arg Gly Tyr Ala Ser Pro Asp Leu Ser Lys Leu Tyr Lys Asn
565 570 575

Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys Lys Val
580 585 590

Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile Glu Leu
595 600 605

Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu Pro Ser
610 615 620

Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr Leu Thr

625 630 635 640

Thr Ser Pro Arg Leu Pro Val Phe
645

<210> 3
<211> 570
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(567)

<400> 3
atg acg gaa tat aag ctg gtg gtg gtg ggc gcc ggc ggt gtg ggc aag 48
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15

agt gcg ctg acc atc cag ctg atc cag aac cat ttt gtg gac gaa tac 96
Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30

gac ccc act ata gag gat tcc tac cgg aag cag gtg gtc att gat ggg 144
Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45

gag acg tgc ctg ttg gac atc ctg gat acc gcc ggc cag gag gag tac 192
Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60

agc gcc atg cgg gac cag tac atg cgc acc ggg gag ggc ttc ctg tgt 240
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80

gtg ttt gcc atc aac aac acc aag tct ttt gag gac atc cac cag tac 288
Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu Asp Ile His Gln Tyr
85 90 95

agg gag cag atc aaa cgg gtg aag gac tcg gat gac gtg ccc atg gtg 336
Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110

ctg gtg ggg aac aag tgt gac ctg gct gca cgc act gtg gaa tct cgg 384
Leu Val Gly Asn Lys Cys Asp Leu Ala Ala Arg Thr Val Glu Ser Arg
115 120 125

cag gct cag gac ctc gcc cga agc tac ggc atc ccc tac atc gag acc 432
Gln Ala Gln Asp Leu Ala Arg Ser Tyr Gly Ile Pro Tyr Ile Glu Thr
130 135 140

tcg gcc aag acc cgg cag gga gtg gag gat gcc ttc tac acg ttg gtg 480
Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160

cgt gag atc cgg cag cac aag ctg cgg aag ctg aac cct cct gat gag 528
Arg Glu Ile Arg Gln His Lys Leu Arg Lys Leu Asn Pro Pro Asp Glu
165 170 175

agt ggc ccc ggc tgc atg agc tgc aag tgt gtg ctc tcc tga 570
Ser Gly Pro Gly Cys Met Ser Cys Lys Cys Val Leu Ser
180 185

<210> 4
<211> 189
<212> PRT
<213> Homo sapiens

<400> 4
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80

Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu Asp Ile His Gln Tyr
85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Ala Ala Arg Thr Val Glu Ser Arg
115 120 125

Gln Ala Gln Asp Leu Ala Arg Ser Tyr Gly Ile Pro Tyr Ile Glu Thr
130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160

Arg Glu Ile Arg Gln His Lys Leu Arg Lys Leu Asn Pro Pro Asp Glu

165 170 175

Ser Gly Pro Gly Cys Met Ser Cys Lys Cys Val Leu Ser
180 185

<210> 5
<211> 6453
<212> DNA
<213> Homo sapiens

<220>
<221> prim_transcript
<222> (1664)..(3744)

<220>
<221> intron
<222> (1775)..(2041)

<220>
<221> intron
<222> (2221)..(2373)

<220>
<221> intron
<222> (2534)..(3230)

<400> 5
ggatcccagc ctttccccag cccgtagccc cgggacctcc gcggtgggcg gcgccgcgct 60

gccggcgcag ggagggcctc tggtgcaccg gcaccgctga gtcgggttct ctcgccggcc 120

tgttcccggg agagcccggg gccctgctcg gagatgccgc cccgggcccc cagacaccgg 180

ctccctggcc ttcctcgagc aaccccgagc tcggctccgg tctccagcca agcccaaccc 240

cgagaggccg cggccctact ggctccgcct cccgcgttgc tcccggaagc cccgcccgac 300

cgcggctcct gacagacggg ccgctcagcc aaccggggtg gggcggggcc cgatggcgcg 360

cagccaatgg taggccgcgc ctggcagacg gacgggcgcg gggcggggcg tgcgcaggcc 420

cgcccgagtc tccgccgccc gtgccctgcg cccgcaaccc gagccgcacc cgccgcggac 480

ggagcccatg cgcggggcga accgcgcgcc cccgcccccg ccccgccccg gcctcggccc 540

cggccctggc cccgggggca gtcgcgcctg tgaacggtga gtgcgggcag ggatcggccg 600

ggccgcgcgc cctcctcgcc cccaggcggc agcaatacgc gcggcgcggg ccgggggcgc 660

ggggccggcg ggcgtaagcg gcggcggcgg cggcgggtgg gtggggccgg gcggggcccg 720

cgggcacagg tgagcgggcg tcgggggctg cggcgggcgg gggccccttc ctccctgggg 780

cctgcgggaa tccgggcccc acccgtggcc tcgcgctggg cacggtcccc acgccggcgt 840

acccgggagc ctcgggcccg gcgccctcac acccgggggc gtctgggagg aggcggccgc 900

ggccacggca cgcccgggca cccccgattc agcatcacag gtcgcggacc aggccggggg 960

cctcagcccc agtgcctttt ccctctccgg gtctcccgcg ccgcttctcg gccccttcct 1020

gtcgctcagt ccctgcttcc caggagctcc tctgtcttct ccagctttct gtggctgaaa 1080

gatgcccccg gttccccgcc gggggtgcgg ggcgctgccc gggtctgccc tcccctcggc 1140

ggcgcctagt acgcagtagg cgctcagcaa atacttgtcg gaggcaccag cgccgcgggg 1200

cctgcaggct ggcactagcc tgcccgggca cgccgtggcg cgctccgccg tggccagacc 1260

tgttctggag gacggtaacc tcagccctcg ggcgcctccc tttagccttt ctgccgaccc 1320

agcagcttct aatttgggtg cgtggttgag agcgctcagc tgtcagccct gcctttgagg 1380

gctgggtccc ttttcccatc actgggtcat taagagcaag tgggggcgag gcgacagccc 1440

tcccgcacgc tgggttgcag ctgcacaggt aggcacgctg cagtccttgc tgcctggcgt 1500

tggggcccag ggaccgctgt gggtttgccc ttcagatggc cctgccagca gctgccctgt 1560

ggggcctggg gctgggcctg ggcctggctg agcagggccc tccttggcag gtggggcagg 1620

agaccctgta ggaggacccc gggccgcagg cccctgagga gcgatgacgg aatataagct 1680

ggtggtggtg ggcgccggcg gtgtgggcaa gagtgcgctg accatccagc tgatccagaa 1740

ccattttgtg gacgaatacg accccactat agaggtgagc ctagcgccgc cgtccaggtg 1800

ccagcagctg ctgcgggcga gcccaggaca cagccaggat agggctggct gcagcccctg 1860

gtcccctgca tggtgctgtg gccctgtctc ctgcttcctc tagaggaggg gagtccctcg 1920

tctcagcacc ccaggagagg agggggcatg aggggcatga gaggtaccag ggagaggctg 1980

gctgtgtgaa ctccccccac ggaaggtcct gagggggtcc ctgagccctg tcctcctgca 2040

ggattcctac cggaagcagg tggtcattga tggggagacg tgcctgttgg acatcctgga 2100

taccgccggc caggaggagt acagcgccat gcgggaccag tacatgcgca ccggggaggg 2160

cttcctgtgt gtgtttgcca tcaacaacac caagtctttt gaggacatcc accagtacag 2220

gtgaaccccg tgaggctggc ccgggagccc acgccgcaca ggtggggcca ggccggctgc 2280

gtccaggcag gggcctcctg tcctctctgc gcatgtcctg gatgccgctg cgcctgcagc 2340

ccccgtagcc agctctcgct ttccacctct cagggagcag atcaaacggg tgaaggactc 2400

ggatgacgtg cccatggtgc tggtggggaa caagtgtgac ctggctgcac gcactgtgga 2460

atctcggcag gctcaggacc tcgcccgaag ctacggcatc ccctacatcg agacctcggc 2520

caagacccgg caggtgaggc agctctccac cccacagcta gccagggacc cgccccgccc 2580

cgccccagcc agggagcagc actcactgac cctctccctt gacacagggc agccgctctg 2640

gctctagctc cagctccggg accctctggg accccccggg acccatgtga cccagcggcc 2700

cctcgcactg taggtctccc gggacggcag ggcagtgagg gaggcgaggg ccggggtctg 2760

ggctcacgcc ctgcagtcct gggccgacac agctccgggg aaggcggagg tccttgggga 2820

gagctgccct gagccaggcc ggagcggtga ccctggggcc cggcccctct tgtccccaga 2880

gtgtcccacg ggcacctgtt ggttctgagt cttagtgggg ctactgggga cacgggccgt 2940

agctgagtcg agagctgggt gcagggtggt caaaccctgg ccagacctgg agttcaggag 3000

ggcccgggc caccctgacc tttgaggggc tgctgtagca tgatgcgggt ggccctgggc 3060

acttcgagat ggccagagtc cagcttcccg tgtgtgtggt gggcctgggg aagtggctgg 3120

tggagtcggg agcttcgggc caggcaaggc ttgatcccac agcagggagc ccctcaccca 3180

ggcaggcggc cacaggccgg tccctcctga tcccatccct cctttcccag ggagtggagg 3240

atgccttcta cacgttggtg cgtgagatcc ggcagcacaa gctgcggaag ctgaaccctc 3300

ctgatgagag tggccccggc tgcatgagct gcaagtgtgt gctctcctga cgcaggtgag 3360

ggggactccc agggcggccg ccacgcccac cggatgaccc cggctccccg cccctgccgg 3420

tctcctggcc tgcggtcagc agcctccctt gtgccccgcc cagcacaagc tcaggacatg 3480

gaggtgccgg atgcaggaag gaggtgcaga cggaaggagg aggaaggaag gacggaagca 3540

aggaaggaag gaagggctgc tggagcccag tcaccccggg accgtgggcc gaggtgactg 3600

cagaccctcc cagggaggct gtgcacagac tgtcttgaac atcccaaatg ccaccggaac 3660

cccagccctt agctcccctc ccaggcctct gtgggccctt gtcgggcaca gatgggatca 3720

cagtaaatta ttggatggtc ttgatcttgg ttttcggctg agggtgggac acggtgcgcg 3780

tgtggcctgg catgaggtat gtcggaacct caggcctgtc cagccctggg ctctccatag 3840
cctttgggag ggggaggttg ggagaggccg gtcaggggtc tgggctgtgg tgctctctcc 3900
tcccgcctgc cccagtgtcc acggcttctg gcagagagct ctggacaagc aggcagatca 3960
taaggacaga gagcttactg tgcttctacc aactaggagg gcgtcctggt cctccagagg 4020
gaggtggttt caggggttgg ggatctgtgc cggtggctct ggtctctgct gggagccttc 4080
ttggcggtga gaggcatcac ctttcctgac ttgctcccag cgtgaaatgc acctgccaag 4140
aatggcagac atagggaccc cgcctcctgg gccttcacat gcccagtttt cttcggctct 4200
gtggcctgaa gcggtctgtg gaccttggaa gtagggctcc agcaccgact ggcctcaggc 4260
ctctgcctca ttggtggtcg ggtagcggcc agtagggcgt gggagcctgg ccatccctgc 4320
ctcctggagt ggacgaggtt ggcagctggt ccgtctgctc ctgccccact ctcccccgcc 4380
cctgccctca ccctaccctt gccccacgcc tgcctcatgg ctggttgctc ttggagcctg 4440
gtagtgtcac tggctcagcc ttgctgggta tacacaggct ctgccaccca ctctgctcca 4500
aggggcttgc cctgccttgg gccaagttct aggtctggcc acagccacag acagctcagt 4560
cccctgtgtg gtcatcctgg cttctgctgg gggcccacag cgcccctggt gcccctcccc 4620
tcccagggcc cgggttgagg ctgggccagg ccctctggga cggggacttg tgccctgtca 4680
gggttcccta tccctgaggt tgggggagag ctagcagggc atgccgctgg ctggccaggg 4740
ctgcagggac actcccccttt ttgtccaggg aataccacac tcgcccttct ctccagcgaa 4800
caccacactc gcccttctct ccaggggacg ccacactccc ccttctgtcc aggggacgcc 4860
acactccccc ttctctccag gggacgccac actcgccctt ctctccaggg gacgccacac 4920
tcgcccttct ctccagggga cgccacactc gcccttctgt ccaggggacg ccacactcgc 4980
ccttctctcc aggggacgcc acactcgccc ttctctccag gggacgccac actccccctt 5040
ctgtccaggg gacgccacac tccccttct ctccagggga cgccacactc cccttctct 5100
ccaggggacg ccacactcgc ccttctctcc aggggacgcc acactccccc ttctgtccag 5160
gggacgccac actcgccctt ctctccaggg gacgccacac tcgcccttct ctccagggga 5220
cgccacactc cccttctct ccaggggacg ccacactccc ccttctctcc aggggacgcc 5280

acactccccc ttctgtccag gggacgccac actcgccctt ctctccaggg gacgccacac 5340

tccccttct ctccagggga cgccacactc cccttctct ccaggggacg ccacactccc 5400

ccttctgtcc aggggacgcc acactcgccc ttctctccag gggacgccac actcgccctt 5460

ctctccaggg gacgccacac tcgcccttct ctccagggga cgccacactt gcccttctgt 5520

ccagggaatg ccacactccc ccttctcccc agcagcctcc gagtgaccag cttccccatc 5580

gatagacttc ccgaggccag gagccctcta gggctgccgg gtgccaccct ggctccttcc 5640

acaccgtgct ggtcactgcc tgctgggggc gtcagatgca ggtgaccctg tgcaggaggt 5700

atctctggac ctgcctcttg gtcattacgg ggctgggcag ggcctggtat cagggccccg 5760

ctggggttgc agggctgggc ctgtgctgtg gtcctggggt gtccaggaca gacgtggagg 5820

ggtcagggcc cagcacccct gctccatgct gaactgtggg aagcatccag gtccctgggt 5880

ggcttcaaca ggagttccag cacgggaacc actggacaac ctggggtgtg tcctgatctg 5940

gggacaggcc agccacaccc cgagtcctag ggactccaga gagcagccca ctgccctggg 6000

ctccacggaa gccccctcat gccgctaggc cttggcctcg gggacagccc agctaggcca 6060

gtgtgtggca ggaccaggcc cccatgtggg agctgacccc ttgggattct ggagctgtgc 6120

tgatgggcag gggagagcca gctcctcccc ttgagggagg gtcttgatgc ctggggttac 6180

ccgcagaggc ctgggtgccg ggacgctccc cggtttggct gaaaggaaag cagatgtggt 6240

cagcttctcc actgagccca tctggtcttc ccggggctgg gccccataga tctgggtccc 6300

tgtgtggccc ccctggtctg atgccgagga tacccctgca aactgccaat cccagaggac 6360

aagactggga agtccctgca gggagagccc atccccgcac cctgacccac aagagggact 6420

cctgctgccc accaggcatc cctccaggga tcc 6453

<210> 6
<211> 2004
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:fusion protein

<220>
<221> CDS

```
<222> (1)..(2004)

<400> 6
atg gag cac ata cag gga gct tgg aag acg atc agc aat ggt ttt gga       48
Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly Phe Gly
  1               5                  10                  15

ttc aaa gat gcc gtg ttt gat ggc tcc agc tgc atc tct cct aca ata       96
Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro Thr Ile
             20                  25                  30

gtt cag cag ttt ggc tat cag cgc cgg gca tca gat gat ggc aaa ctc      144
Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly Lys Leu
         35                  40                  45

aca gat cct tct aag aca agc aac act atc cgt gtt ttc ttg ccg aac      192
Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu Pro Asn
     50                  55                  60

aag caa aga aca gtg gtc aat gtg cga aat gga atg agc ttg cat gac      240
Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu His Asp
 65                  70                  75                  80

tgc ctt atg aaa gca ctc aag gtg agg ggc ctg caa cca gag tgc tgt      288
Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu Cys Cys
                 85                  90                  95

gca gtg ttc aga ctt ctc cac gaa cac aaa ggt aaa aaa gca cgc tta      336
Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala Arg Leu
            100                 105                 110

gat tgg aat act gat gct gcg tct ttg att gga gaa gaa ctt caa gta      384
Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu Gln Val
        115                 120                 125

gat ttc ctg gat cat gtt ccc ctc aca aca cac aac ttt gct cgg aag      432
Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala Arg Lys
    130                 135                 140

acg ttc ctg aag ctt gcc ttc tgt gac atc tgt cag aaa ttc ctg ctc      480
Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe Leu Leu
145                 150                 155                 160

aat gga ttt cga tgt cag act tgt ggc tac aaa ttt cat gag cac tgt      528
Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu His Cys
                165                 170                 175

agc acc aaa gta cct act atg tgt gtg gac tgg agt aac atc aga caa      576
Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile Arg Gln
            180                 185                 190
```

```
ctc tta ttg ttt cca aat tcc act att ggt gat agt gga gtc cca gca     624
Leu Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val Pro Ala
        195                 200                 205

cta cct tct ttg act atg cgt cgt atg cga gag tct gtt tcc agg atg     672
Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser Arg Met
    210                 215                 220

cct gtt agt tct cag cac aga tat tct aca cct cac gcc ttc acc ttt     720
Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe Thr Phe
225                 230                 235                 240

aac acc tcc agt ccc tca tct gaa ggt tcc ctc tcc cag agg cag agg     768
Asn Thr Ser Ser Pro Ser Ser Glu Gly Ser Leu Ser Gln Arg Gln Arg
                245                 250                 255

tcg aca tcc aca cct aat gtc cac atg gtc agc acc acg ctg cct gtg     816
Ser Thr Ser Thr Pro Asn Val His Met Val Ser Thr Thr Leu Pro Val
            260                 265                 270

gac agc agg atg att gag gat gca att cga agt cac agc gaa tca gcc     864
Asp Ser Arg Met Ile Glu Asp Ala Ile Arg Ser His Ser Glu Ser Ala
        275                 280                 285

tca cct tca gcc ctg tcc agt agc ccc aac aat ctg agc cca aca ggc     912
Ser Pro Ser Ala Leu Ser Ser Ser Pro Asn Asn Leu Ser Pro Thr Gly
    290                 295                 300

tgg tca cag ccg aaa acc ccc gtg cca gca caa aga gag cgg gca cca     960
Trp Ser Gln Pro Lys Thr Pro Val Pro Ala Gln Arg Glu Arg Ala Pro
305                 310                 315                 320

gta tct ggg acc cag gag aaa aac aaa att agg cct cgt gga cag aga    1008
Val Ser Gly Thr Gln Glu Lys Asn Lys Ile Arg Pro Arg Gly Gln Arg
                325                 330                 335

gat tca agc tat tat tgg gaa ata gaa gcc agt gaa gtg atg ctg tcc    1056
Asp Ser Ser Tyr Tyr Trp Glu Ile Glu Ala Ser Glu Val Met Leu Ser
            340                 345                 350

act cgg att ggg tca ggc tct ttt gga act gtt tat aag ggt aaa tgg    1104
Thr Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp
        355                 360                 365

cac gga gat gtt gca gta aag atc cta aag gtt gtc gac cca acc cca    1152
His Gly Asp Val Ala Val Lys Ile Leu Lys Val Val Asp Pro Thr Pro
    370                 375                 380

gag caa ttc cag gcc ttc agg aat gag gtg gct gtt ctg cgc aaa aca    1200
Glu Gln Phe Gln Ala Phe Arg Asn Glu Val Ala Val Leu Arg Lys Thr
385                 390                 395                 400
```

```
cgg cat gtg aac att ctg ctt ttc atg ggg tac atg aca aag gac aac   1248
Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Met Thr Lys Asp Asn
                405                 410                 415

ctg gca att gtg acc cag tgg tgc gag ggc agc agc ctc tac aaa cac   1296
Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr Lys His
            420                 425                 430

ctg cat gtc cag gag acc aag ttt cag atg ttc cag cta att gac att   1344
Leu His Val Gln Glu Thr Lys Phe Gln Met Phe Gln Leu Ile Asp Ile
        435                 440                 445

gcc cgg cag acg gct cag gga atg gac tat ttg cat gca aag aac atc   1392
Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Asn Ile
    450                 455                 460

atc cat aga gac atg aaa tcc aac aat ata ttt ctc cat gaa ggc tta   1440
Ile His Arg Asp Met Lys Ser Asn Asn Ile Phe Leu His Glu Gly Leu
465                 470                 475                 480

aca gtg aaa att gga gat ttt ggt ttg gca aca gta aag tca cgc tgg   1488
Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp
                485                 490                 495

agt ggt tct cag cag gtt gaa caa cct act ggc tct gtc ctc tgg atg   1536
Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu Trp Met
            500                 505                 510

gcc cca gag gtg atc cga atg cag gat aac aac cca ttc agt ttc cag   1584
Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser Phe Gln
        515                 520                 525

tcg gat gtc tac tcc tat ggc atc gta ttg tat gaa ctg atg acg ggg   1632
Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met Thr Gly
    530                 535                 540

gag ctt cct tat tct cac atc aac aac cga gat cag atc atc ttc atg   1680
Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile Phe Met
545                 550                 555                 560

gtg ggc cga gga tat gcc tcc cca gat ctt agt aag cta tat aag aac   1728
Val Gly Arg Gly Tyr Ala Ser Pro Asp Leu Ser Lys Leu Tyr Lys Asn
                565                 570                 575

tgc ccc aaa gca atg aag agg ctg gta gct gac tgt gtg aag aaa gta   1776
Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys Lys Val
            580                 585                 590

aag gaa gag agg cct ctt ttt ccc cag atc ctg tct tcc att gag ctg   1824
Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile Glu Leu
```

```
        595                 600                 605

ctc caa cac tct cta ccg aag atc aac cgg agc gct tcc gag cca tcc      1872
Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu Pro Ser
    610                 615                 620

ttg cat cgg gca gcc cac act gag gat atc aat gct tgc acg ctg acc      1920
Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr Leu Thr
625                 630                 635                 640

acg tcc ccg agg ctg cct gtc ttc tac tcg ttc ctg ccg ttc ttc ttc      1968
Thr Ser Pro Arg Leu Pro Val Phe Tyr Ser Phe Leu Pro Phe Phe Phe
                645                 650                 655

ttc ttc ttc tcg ttc tgt ttc acg cct agt aca ttc                      2004
Phe Phe Phe Ser Phe Cys Phe Thr Pro Ser Thr Phe
            660                 665


<210> 7
<211> 668
<212> PRT
<213> Artificial Sequence

<400> 7
Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly Phe Gly
  1               5                  10                  15

Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro Thr Ile
            20                  25                  30

Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly Lys Leu
        35                  40                  45

Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu Pro Asn
    50                  55                  60

Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu His Asp
65                  70                  75                  80

Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu Cys Cys
                85                  90                  95

Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala Arg Leu
            100                 105                 110

Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu Gln Val
        115                 120                 125

Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala Arg Lys
    130                 135                 140
```

```
Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe Leu Leu
145                 150                 155                 160

Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu His Cys
                165                 170                 175

Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile Arg Gln
            180                 185                 190

Leu Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val Pro Ala
        195                 200                 205

Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser Arg Met
    210                 215                 220

Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe Thr Phe
225                 230                 235                 240

Asn Thr Ser Ser Pro Ser Ser Glu Gly Ser Leu Ser Gln Arg Gln Arg
                245                 250                 255

Ser Thr Ser Thr Pro Asn Val His Met Val Ser Thr Thr Leu Pro Val
            260                 265                 270

Asp Ser Arg Met Ile Glu Asp Ala Ile Arg Ser His Ser Glu Ser Ala
        275                 280                 285

Ser Pro Ser Ala Leu Ser Ser Ser Pro Asn Asn Leu Ser Pro Thr Gly
    290                 295                 300

Trp Ser Gln Pro Lys Thr Pro Val Pro Ala Gln Arg Glu Arg Ala Pro
305                 310                 315                 320

Val Ser Gly Thr Gln Glu Lys Asn Lys Ile Arg Pro Arg Gly Gln Arg
                325                 330                 335

Asp Ser Ser Tyr Tyr Trp Glu Ile Glu Ala Ser Glu Val Met Leu Ser
            340                 345                 350

Thr Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp
        355                 360                 365

His Gly Asp Val Ala Val Lys Ile Leu Lys Val Val Asp Pro Thr Pro
    370                 375                 380

Glu Gln Phe Gln Ala Phe Arg Asn Glu Val Ala Val Leu Arg Lys Thr
385                 390                 395                 400

Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Met Thr Lys Asp Asn
                405                 410                 415
```

```
Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr Lys His
            420                 425                 430

Leu His Val Gln Glu Thr Lys Phe Gln Met Phe Gln Leu Ile Asp Ile
        435                 440                 445

Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Asn Ile
    450                 455                 460

Ile His Arg Asp Met Lys Ser Asn Asn Ile Phe Leu His Glu Gly Leu
465                 470                 475                 480

Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp
                485                 490                 495

Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu Trp Met
            500                 505                 510

Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser Phe Gln
        515                 520                 525

Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met Thr Gly
    530                 535                 540

Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile Phe Met
545                 550                 555                 560

Val Gly Arg Gly Tyr Ala Ser Pro Asp Leu Ser Lys Leu Tyr Lys Asn
                565                 570                 575

Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys Lys Val
            580                 585                 590

Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile Glu Leu
        595                 600                 605

Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu Pro Ser
    610                 615                 620

Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr Leu Thr
625                 630                 635                 640

Thr Ser Pro Arg Leu Pro Val Phe Tyr Ser Phe Leu Pro Phe Phe Phe
                645                 650                 655

Phe Phe Phe Ser Phe Cys Phe Thr Pro Ser Thr Phe
            660                 665
```

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

My residence, post office address, and citizenship are as stated next to my name in PART A on page 2 hereof.

I believe I am the original, first, and sole inventor (if only one name is listed) or an original, first, and joint inventor (if plural names are listed) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHODS AND COMPOSITIONS USEFUL FOR MODULATION OF ANGIOGENESIS USING TYROSINE KINASE RAF AND RAS**, the specification of which:

X is attached hereto;

___ was filed on _____ as Application Serial No. _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to herein.

I acknowledge the duty to disclose information to the Patent and Trademark Office known to me to be material to the patentability of this application, as defined in Title 37, Code of Federal Regulations, Sec. 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 of any foreign application(s) for patent or inventor's certificate listed in PART B on page 2 hereof and have also identified in PART B on page 2 hereof any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, Sec. 120 of any United States application(s) listed in PART C of page 2 hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 25, United States Code, Sec. 112, I acknowledge the duty to disclose all information to the Patent and Trademark Office known to me to be material to patentability of this application, as defined in Title 37, Code of Federal Regulations, Sec. 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following as my attorneys or agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Michael A. Hierl	Reg. No. 29,807	Arne M. Olson	Reg. No. 30,203
Dolores T. Kenney	Reg. No. 31,269	Talivaldis Cepuritis	Reg. No. 20,818
Seymour Rothstein	Reg. No. 19,369	Daniel J. Deneufbourg	Reg. No. 33,675
Richard L. Robinson	Reg. No. 31,415	Joseph M. Kuo	Reg. No. 38,943
Mark Chao	Reg. No. 37,293	Martin J. Corn	Reg. No. 35,847

Whose mailing address for this application is:

OLSON & HIERL, LTD.
20 North Wacker Drive - 36th Floor
Chicago, Illinois 60606
Telephone: (312) 580-1180

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

PART A: Inventor Information and Signature

Full name of SOLE or FIRST inventor **John Hood**
Citizenship U.S. Residence 532.5J Via de la Valle
Solana Beach, California 92075
Post Office Address (If different) _____

Inventor's signature: _____ Date: _____

Full name of SECOND Inventor **Brian Eliceiri**
Citizenship U.S. Residence 3104 Hataca Road
Carlsbad, California 92009
Post Office Address (If different) _____

Inventor's signature: _____ Date: _____

Full name of THIRD Inventor **David A. Cheresh**
Citizenship U.S. Residence 3277 Lone Hill Lane
Encinitas, California 92024
Post Office Address (If different) _____

Inventor's signature: _____ Date: _____

PART B: Prior Foreign Application(s)

Serial No.	Country	Day/Month/Year Filed	Priority Claimed

PART C: Claim for Benefit of Filing Date of Earlier U.S. Application(s)

Serial No.	Filing Date	Status
60/148,924	August 13, 1999	
60/215,951	July 5, 2000	

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division

Application deficiencies were found during scanning:

☐ Page(s)__________ of ______________________________ were not present for scanning.
(Document title)

☐ Page(s)__________ of ______________________________ were not present for scanning.
(Document title)

☑ Scanned copy is best available. Drawings.